Podcasts about Francis Crick Institute

Julie Gould compares hiring practices across industry and academia by seeking perspectives from Tina Persson, an organic chemist-turned-careers coach based in Malmö, Sweden, and Lauren Celano, a recruitment consultant who founded Propel Careers, based in Boston, Massachusetts, in 2009.Persson, whose coaching business is called passage2pro, tells Gould why it typically takes longer to hire scientists in academia. Margot Smit, a plant molecular biologist who now recruits scientists for her lab at Tübingen University in Germany, reflects on her own experiences as an academic jobseeker in 2022. It involved panel interviews, lab tours, team dinners, and, in one case, a symposium where all candidates gave a talk. Now, as someone who recruits scientists to her lab, she involves junior colleagues in hiring decisions.Jen Heemstra tells a similar tale. Her search for a department chair position in 2022 meant moving not only herself but also her entire chemistry research group to Washington University in St. Louis. She explains how she updated her colleagues and addressed their questions and concerns about the impending move.Finally, Rachel Howard describes how she hopes to make the process quicker and easier for hiring managers at the Francis Crick Institute in London, where she is head of talent acquisition. Hosted on Acast. See acast.com/privacy for more information.

The Smart 7 is an award winning daily podcast, in association with METRO that gives you everything you need to know in 7 minutes, at 7am, 7 days a week...With over 17 million downloads and consistently charting, including as No. 1 News Podcast on Spotify, we're a trusted source for people every day and the Sunday 7 won a Gold Award as “Best Conversation Starter” in the International Signal Podcast Awards If you're enjoying it, please follow, share, or even post a review, it all helps...Today's episode includes the following guests:Guests: Beth Shapiro - Chief Scientist at Colossal Biosciences Professor Robin Alta Charo - Professor of Law and BioEthics at the University of Wisconsin - Madison Pontus Skoglund - Group Leader of the Francis Crick Institute's Ancient Genomics Laboratory Will Guyatt - The Smart 7's Tech Guru Grace Davidson - Womb Transplant Recipient and Mother of Amy Isabel Isabel Quiroga - Consultant Surgeon at the Oxford Transplant Centre, Professor Richard Smith - Clinical lead at the charity Womb Transplant UK and Consultant Gynaecological surgeon at Imperial College Healthcare NHS Trust Artemizia Marubo - Nurse at the Medical Centre in the Javari Valley in the Amazon Doctor David Persse - Houston Health Department Dr Peter Marks - Former Director of the Center for Biologics Evaluation and ResearchDonald Trump - President of the United States of America Marko Bjelonic -Inventor & Chief Dog handler, at Robot company RIVR Lauren Augustine - Director of Herpetology at the Philadelphia Zoo Contact us over @TheSmart7pod or visit www.thesmart7.com or find out more at www.metro.co.uk This Episode is presented by Mike Wooller, written by Liam Thompson and produced by Daft Doris. Hosted on Acast. See acast.com/privacy for more information.

In this episode of The Cancer Researcher Podcast we interview Professor Charlie Swanton, Deputy Clinical Director of the Francis Crick Institute and Chief Clinician at Cancer Research UK on his research interests, the evolution of the field and how he turned round his failing PhD. Charlie also shares with us what he's looking forward to at the EACR Congress ahead of his Keynote Lecture and gives some excellent advice to early-career researchers on how to break away from the shyness that could hold some back from asking questions and networking at conferences.

Sam Rodriques is an inventor and entrepreneur. In 2023, he launched FutureHouse, a new research lab in San Francisco focused on building an AI Scientist. He previously ran the Applied Biotechnology Lab at the Francis Crick Institute. Before that, he did his PhD at MIT. Sam also proposed the Focused Research Organization model, which is now being used by a number of philanthropic funders and governments to facilitate scientific moonshots.About Foresight InstituteForesight Institute is a research organization and non-profit that supports the beneficial development of high-impact technologies. Since our founding in 1987 on a vision of guiding powerful technologies, we have continued to evolve into a many-armed organization that focuses on several fields of science and technology that are too ambitious for legacy institutions to support.Get Involved with Foresight:Apply to our virtual technical seminars Join our in-person events and workshops Donate: Support Our Work – If you enjoy what we do, please consider this, as we are entirely funded by your donations!Follow Us: Twitter | Facebook | LinkedIn Hosted on Acast. See acast.com/privacy for more information.

Steph and Robert speak to Sir Paul Nurse - Nobel Prize winning cell biologist and Director of the Francis Crick Institute - about how science funding needs to change, why the UK is failing to lure global talent, how we scrub up against the other OECD countries in terms of research and development and how - despite being a geneticist - it took him 55 years to discover who his biological parents were. Email: restismoney@gmail.com X: @TheRestIsMoney Instagram: @TheRestIsMoney TikTok: @RestIsMoney goalhangerpodcasts.com Assistant Producer: India Dunkley, Alice Horrell, Evan Green Producer: Ross Buchanan Head of Content: Tom Whiter Exec Producers: Tony Pastor + Jack Davenport Learn more about your ad choices. Visit podcastchoices.com/adchoices

Cancer is a disease that will affect 1 in 5 people in our lifetime, and it's estimated that around 20 million people worldwide will be diagnosed with some form of cancer in 2025.But how might a vaccine help in the treatment of cancer?Numerous trials began testing the viability of cancer vaccines in 2024, including one for Melanoma and another for Lung Cancer. With all the promise that these new cancer vaccine trials bring for cancer patients, we explore the different ways in which vaccines could work within the body, and how the time at which future vaccines are administered may vary according to the cancers they are targeting.This week on the Inquiry we're asking: Are we close to a cancer vaccine?Presenter: Tanya Beckett Producer: Matt Toulson Researcher: Katie Morgan Production Coordinator: Tim Fernley Editor: Tara McDermott Studio Director: Craig Boardman Contributors: Meredith McKean, director of Melanoma and Skin Cancer Research for Sarah Cannon Research Institute at Tennessee OncologySamra Turajlic, Chief Investigator of translational studies into melanoma and kidney cancer at the Francis Crick Institute and Professor at the Institute of Cancer Research Eduardo Vilar-Sanchez, professor in the department of Clinical Cancer Prevention at The University of Texas MD Anderson Cancer CenterPatrick Ott, Clinical Director at Melanoma Disease Center at the Dana-Farber Institute

The UK Health Security Agency has issued an amber ‘cold-health alert' warning for London amid plunging temperatures and a forecast for snow at the weekend.London plunged below zero overnight, with a ”feels-like” temperature of -4C on Friday morning - and more low single-digit chills forecast next week.Nationally, the cold weather blast has seen temperatures drop to -5C overnight with warning of -8C next week.It comes just weeks after devastating floods caused by Storm Darragh. The Standard podcast is joined by Met Office meteorologist Alex Deakin and Mhairi Sharp, chief executive of the National Emergencies Trust.In part two, could a new type of DNA analysis technique on crushed-up ancient bone fragments rewrite of some of Britain's key moments in ancient history?We're joined by King's College London professor of medieval history Peter Heather to discuss the joint research with the Francis Crick Institute. Hosted on Acast. See acast.com/privacy for more information.

We're experimenting and would love to hear from you!In this episode of Discover Daily, we delve into new research on AI alignment faking, where Anthropic and Redwood Research reveal how AI models can strategically maintain their original preferences despite new training objectives. The study shows Claude 3 Opus exhibiting sophisticated behavior patterns, demonstrating alignment faking in 12% of cases and raising crucial questions about the future of AI safety and control.Scientists at the Francis Crick Institute achieve a remarkable breakthrough in developmental biology by successfully growing a human notochord in the laboratory using stem cells. This milestone advancement provides unprecedented insights into spinal development and opens new possibilities for treating various spinal conditions, including degenerative disc diseases and birth defects. The researchers utilized precise molecular signaling techniques to create both the notochord and 3D spinal organoid models.Queensland University of Technology researchers unveil a revolutionary ultra-thin thermoelectric film that converts body heat into electricity, potentially transforming the future of wearable technology. This 0.3mm-thick film generates up to 35 microwatts per square centimeter and could eliminate the need for traditional batteries in medical devices, fitness trackers, and smart clothing. The breakthrough represents a significant step toward sustainable, self-powered wearable devices and could revolutionize the electronics industry.From Perplexity's Discover Feed:https://www.perplexity.ai/page/ai-pretends-to-change-views-J_di6ttzRwizbAWCDL5RRAhttps://www.perplexity.ai/page/human-spine-grown-in-lab-amLfZoZjQTuFNY5Xjlm2BAhttps://www.perplexity.ai/page/body-heat-powered-wearables-br-HAOPtm7TSFCPqBR6qVq0cAPerplexity is the fastest and most powerful way to search the web. Perplexity crawls the web and curates the most relevant and up-to-date sources (from academic papers to Reddit threads) to create the perfect response to any question or topic you're interested in. Take the world's knowledge with you anywhere. Available on iOS and Android Join our growing Discord community for the latest updates and exclusive content. Follow us on: Instagram Threads X (Twitter) YouTube Linkedin

“Cell division is fundamental to the growth of every living thing and when it goes wrong and is out of control this is the basis for all cancers and understanding this process is important,” explained Sir Paul Nurse. When it comes to understanding the fundamentals of cell division and the cancer connection, Sir Paul is a world-renowned expert and pioneer. He was awarded the Nobel Prize in Physiology or Medicine in 2001. In this podcast, he explained the ideas that sparked his ground-breaking research and how his findings gave scientists around the world the insight and tools they needed to develop advanced cancer therapeutics such as immunotherapy. Sir Paul is adept at explaining his work and the complexities of science in easy-to-understand language, combined with his keen intellect, modesty and a warm sense of humor. He's someone you will enjoy spending time with. As a young scientist, Sir Paul said he knew there would be a lot of ups and downs, and he was determined “to study something important and what is more fundamental than the process that is the basis of all growth … I didn't do this to cure cancer, but to understand the principles behind dividing cells and I thought by understanding this it would have implications for cancer and other diseases.” Sir Paul, director and chief executive of the Francis Crick Institute in London, was recently in Columbus as the recipient of the 26th Annual Herbert and Maxime Block Memorial Lectureship Award for Distinguished Achievement in Cancer. In addition to delivering a lecture, the Block Lectureship includes a mentor/mentee collaboration between Sir Paul and Li-Chun Tu, PhD, an Ohio State and OSUCCC-James assistant professor in the Department of Biological Chemistry and Pharmacology. Dr. Tu joined the second half of this podcast, and described her work in genetics. Sir Paul and Dr. Tu look forward to working together. “I truly believe he will give me such good advice,” Dr. Tu said.

Since the early 1990s, there's been a concerning uptick in cancer incidence among adults younger than 50 years. Scientists are racing to understand what's driving these trends. Some evidence points to roles for established risk factors – including smoking and obesity. But some research is also exploring environmental exposures – such as microplastics and forever chemicals – and asking if these could be changing the microbiome and potentially causing inflammation within the body.  So what do these trends mean for cancer research, for health services and national policy? And faced with such stark trends, where are there grounds for hope?  To discuss, our Chief Executive Jennifer Dixon is joined by: Kimmie Ng, specialist in oncology and Director of the Young-Onset Colorectal Cancer Centre at the Dana Farber Cancer Institute in Boston, and Associate Professor of Medicine at Harvard Medical School.  Charles Swanton, Deputy Clinical Director at Francis Crick Institute, Chief Clinician at Cancer Research UK, and a consultant oncologist at University College London Hospitals NHS Foundation Trust. Show notes Nature Reviews Clinical Oncology (2022). Is early-onset cancer an emerging global epidemic? Current evidence and future implications. BMJ Oncology (2023). Global trends in incidence, death, burden and risk factors of early-onset cancer from 1990 to 2019. Gupta S et al (2023). Birth Cohort Colorectal Cancer (CRC): Implications for research and practice. Financial Times (2023). The unexplained rise of cancer among millennials.The New England Journal of Medicine (2024). Microplastics and nanoplastics in atheromas and cardiovascular events. Cancer Grand Challenges. Team OPTIMISTICC: Opportunity to investigate the microbiome's impact on science and treatment in colorectal cancer. The Health Foundation (2023). How chronic stress weathers our health.  The Health Foundation (2024). Rising cancer incidence in younger adults: what is going on?  (Forthcoming)

Send us a Text Message.About the guest: Caetano Reis e Sousa, DPhil is an immunologist and Principal Group Leader at the Francis Crick Institute in London. His lab studies immune system function, including its ability to fight infection and cancer.Episode summary: Nick and Dr. Reis e Sousa discuss: dendritic cells & innate immunity; how the immune system recognizes pathogens, damaged cells, and cancer cells; gut microbiome & non-pathogenic bacteria; inflammation; vitamin D & gut-immune interactions; cancer; and more.Related episodes:Ketogenic Diet, Cancer, Microbiome, Nutrition & the Immune System | Maayan Levy | #72Microbiome-Gut-Brain Axis in Health & Disease | John Cryan | #63*This content is never meant to serve as medical advice.Support the Show.All episodes (audio & video), show notes, transcripts, and more at the M&M Substack Try Athletic Greens: Comprehensive & convenient daily nutrition. Free 1-year supply of vitamin D with purchase.Try SiPhox Health—Affordable, at-home bloodwork w/ a comprehensive set of key health marker. Use code TRIKOMES for a 10% discount.Try the Lumen device to optimize your metabolism for weight loss or athletic performance. Use code MIND for 10% off.Learn all the ways you can support my efforts

The first of the three influenza pandemics that occurred in the 20th century is estimated to have killed over 50 million people.  Based on scientific advances, what do we know about the 1918-20 pandemic? What lessons does it teach about preventing pandemics and containing outbreaks when they do occur?Richard Pebody, director clinical and emerging infections of the UKs health security agency, explores the deadly 1918-20 pandemic. Thorsten Wolff, head of the Division for Influenza and other Respiratory Viruses, talks us through the scientific discoveries that helped to explain the virus that caused the 1918-20 pandemic, and the ongoing work of the National Influenza centre in Berlin. Nicola Lewis, Director of the Worldwide Centre for Influenza at the Francis Crick Institute, UK, explains their work to monitor seasonal flu and pick up changes in flu strains that could have pandemic potential.

Half the UK population will get cancer during their lifetime - and rates are rising. Each year, around 385,000 people in the UK are diagnosed and around 167,00 lives are lost to the disease. But scientists are developing new therapies, including personalised vaccines and targeted drugs, that attack cancer cells directly and more effectively. It's hoped this pioneering work could lead to better survival rates. David Aaronovitch and guests discuss promising developments in cancer care - to find out how significant they might be. Guests: Professor Charles Swanton, chief clinician at Cancer Research UK and deputy clinical director at the Francis Crick Institute; Dr Olivia Rossanese, Director of the Centre for Cancer Drug Discovery at the Institute of Cancer Research; Christian Ottensmeier, Professor of Immuno-Oncology at the University of Liverpool; Professor Alan Melcher, Consultant Clinical Oncologist at The Royal Marsden NHS Foundation TrustPresenter: David Aaronovitch Producers: Rosamund Jones and Sally Abrahams Sound engineers: Rod Farquhar and Neil Churchill Editor: Richard Vadon

Thank you to the folks at Sustain (https://sustainoss.org/) for providing the hosting account for CHAOSSCast! CHAOSScast – Episode 88 In this episode of CHAOSSScast, host Alice Sowerby, along with Dawn Foster and Elizabeth Barron, discuss measuring and improving open source community health through contributor sustainability. The conversation highlights the importance of documentation, the balance of contributor roles, and proactive community building. They share insights and examples on how projects can avoid single points of failure, the significance of onboarding processes, and the impact of asking for help. The discussion also underscores the human aspects of open source contributions and provides practical strategies for long-term project viability. Press download now to hear more! [00:02:11] Dawn explains that practitioner guides are designed for non-experts to help interpret data on open source projects, highlighting the overwhelming amount of data involved. [00:03:24] Dawn mentions the first four practitioner guides, including an introductory guide, and specific guides on contributor sustainability, responsiveness, and organizational participation. [00:04:14] Alice asks why contributor sustainability is so important, to which Dawn responds that it significantly impacts overall project sustainability. She references the xkcd dependency comic to illustrate the vulnerability of projects reliant on few contributors. [00:05:41] Elizabeth notes the increasing awareness of proactive approach towards ensuring contributor sustainability in open source. [00:06:33] Dawn discusses specific metrics like the contributor absence factor, emphasizing the importance of a balanced contributor base. She shares a story about a Java project stalling due to the sole maintainer's incarceration. [00:08:50] There's a discussion about the importance of recognizing diverse contributions beyond code, such as community management and documentation. Dawn highlights the efficiency that professional roles can bring to these areas. [00:11:39] Elizabeth shares concerns about a specific open source project with a large user base but limited active contributors, highlighting the risks involved. Dawn briefly mentions the structure of the practitioner guides, particularly focusing on the steps for making improvements in project sustainability. [00:15:57] Elizabeth emphasizes the importance of making documentation not only informative but also welcoming, and Dawn suggests ways to make contributions easier. [00:18:43] Elizabeth highlights the value of recognition in open source communities, Dawn discusses the idea of expanding roles within projects beyond the binary of contributors and maintainers, and there's a discussion on the importance of distributing work among several people to avoid over-reliance on a single contributor. [00:21:55] Dawn shares that improving contributor sustainability is a long-term effort and suggests staring with areas that can make the biggest impact. Elizabeth reflects on the psychological aspect of maintainers having to share control of projects, which can be challenging but is necessary for project growth and sustainability. [00:27:39] Elizabeth expresses a desire to see more open source projects include community building or growth as a deliberate part of their roadmaps, and Dawn encourages feedback on the practitioner guides to improve them, highlighting the importance of community input in enhancing these resources. Value Adds (Picks) of the week: [00:29:52] Alice's pick is a paper she recently read on “Dark matter could be primordial black holes,” and a discovery by the Francis Crick Institute in London of a biological pathway that's a major driver of IBD. [00:31:21] Dawn's pick is re-watching “Friends” TV show. [00:31:52] Elizabeth's pick is watching “Lord of the Rings Trilogy” at the movie theatre. Panelists: Alice Sowerby Dawn Foster Elizabeth Barron Links: CHAOSS (https://chaoss.community/) CHAOSS Project X/Twitter (https://twitter.com/chaossproj?lang=en) CHAOSScast Podcast (https://podcast.chaoss.community/) podcast@chaoss.community-email (mailto:podcast@chaoss.community-email) Dawn Foster X/Twitter (https://twitter.com/geekygirldawn?lang=en) Alice Sowerby Website (https://www.rosmarin.co.uk/) Elizabeth Barron X/Twitter (https://twitter.com/elizabethn) CHAOSScast Podcast-Episode 85: Introducing CHAOSS Practitioner Guides: #1 Responsiveness (https://podcast.chaoss.community/85) Practitioner Guide: Contributor Sustainability-CHAOSS (https://chaoss.community/practitioner-guide-contributor-sustainability/) xkcd-Dependency (https://xkcd.com/2347/) Colorful Primordial Black Holes (https://physics.aps.org/articles/v17/s69) IBD Breakthrough (https://www.theguardian.com/society/article/2024/jun/05/bowel-disease-hope-researchers-find-biological-pathway)

A special episode from this year's annual Royal Society Summer Exhibition in London, with Claudia Hammond joined by BBC health and science correspondent, James Gallagher, to take a look at a range of new health research. The exhibitions include a look at how special forms of UV light might be able to cut away cancerous cells in brain tumours, with the possibility of light emitting bandages also being used to target cancer treatments. Claudia and James also look at research from The Francis Crick Institute into whether a simple blood test can help work out how to quickly identify patients who are most likely to deteriorate when they have a virus. We also hear how much brain devices we can buy online really tell us about our brain activity, as well as research into how the way babies wriggle may help identify future developmental issues. Claudia and James also compete in a number of scientific games to see who is this year's Summer Exhibition champion. Presenter: Claudia Hammond Producer: Dan Welsh

フランシス・クリック研究所を視察される天皇陛下、２６日、ロンドン【ロンドン時事】英国訪問中の天皇陛下は２６日午前、ロンドンの「フランシス・クリック研究所」を視察された。 Japanese Emperor Naruhito on Wednesday visited the Francis Crick Institute in London, one of the largest biomedical research centers in Europe.

Sono stati resi noti i dati di una ricerca estremamente interessante che collega la vitamina D alla resistenza al cancro attraverso il microbioma intestinale.Ricercatori del Francis Crick Institute hanno scoperto che la vitamina D promuove la crescita di uno specifico tipo di batterio intestinale, Bacteroides fragilis, che migliora l'immunità contro il cancro.

The most enthralling conversation I've ever had with anyone on cancer. It's with Charlie Swanton who is a senior group leader at the Francis Crick Institute, the Royal Society Napier Professor in Cancer and medical oncologist at University College London, co-director of Cancer Research UK.Video snippet from our conversation. Full videos of all Ground Truths podcasts can be seen on YouTube here. The audios are also available on Apple and Spotify.Transcript with audio links and many external linksEric Topol (00:07):Well, hello, this is Eric Topol with Ground Truths, and I am really fortunate today to connect us with Charlie Swanton, who is if not the most prolific researcher in the space of oncology and medicine, and he's right up there. Charlie is a physician scientist who is an oncologist at Francis Crick and he heads up the lung cancer area there. So Charlie, welcome.Charles Swanton (00:40):Thank you, Eric. Nice to meet you.Learning from a FailureEric Topol (00:43):Well, it really is a treat because I've been reading your papers and they're diverse. They're not just on cancer. Could be connecting things like air pollution, it could be Covid, it could be AI, all sorts of things. And it's really quite extraordinary. So I thought I'd start out with a really interesting short paper you wrote towards the end of last year to give a sense about you. It was called Turning a failing PhD around. And that's good because it's kind of historical anchoring. Before we get into some of your latest contributions, maybe can you tell us about that story about what you went through with your PhD?Charles Swanton (01:26):Yeah, well thank you, Eric. I got into research quite early. I did what you in the US would call the MD PhD program. So in my twenties I started a PhD in a molecular biology lab at what was then called the Imperial Cancer Research Fund, which was the sort of the mecca for DNA tumor viruses, if you like. It was really the place to go if you wanted to study how DNA tumor viruses worked, and many of the components of the cell cycle were discovered there in the 80s and 90s. Of course, Paul Nurse was the director of the institute at the time who discovered cdc2, the archetypal regulator of the cell cycle that led to his Nobel Prize. So it was a very exciting place to work, but my PhD wasn't going terribly well. And sort of 18, 19 months into my PhD, I was summoned for my midterm reports and it was not materializing rapidly enough.(02:25):And I sat down with my graduate student supervisors who were very kind, very generous, but basically said, Charlie, this isn't going well, is it? You've got two choices. You can either go back to medical school or change PhD projects. What do you want to do? And I said, well, I can't go back to medical school because I'm now two years behind. So instead I think what I'll do is I'll change PhD projects. And they asked me what I'd like to do. And back then we didn't know how p21, the CDK inhibitor bound to cyclin D, and I said, that's what I want to understand how these proteins interact biochemically. And they said, how are you going to do that? And I said, I'm not too sure, but maybe we'll try yeast two-hybrid screen and a mutagenesis screen. And that didn't work either. And in the end, something remarkable happened.(03:14):My PhD boss, Nic Jones, who's a great guy, still is, retired though now, but a phenomenal scientist. He put me in touch with a colleague who actually works next door to me now at the Francis Crick Institute called Neil McDonald, a structural biologist. And they had just solved, well, the community had just solved the structure. Pavletich just solved the structure of cyclin A CDK2. And so, Neil could show me this beautiful image of the crystal structure in 3D of cyclin A, and we could mirror cyclin D onto it and find the surface residue. So I spent the whole of my summer holiday mutating every surface exposed acid on cyclin D to an alanine until I found one that failed to interact with p21, but could still bind the CDK. And that little breakthrough, very little breakthrough led to this discovery that I had where the viral cyclins encoded by Kaposi sarcoma herpes virus, very similar to cyclin D, except in this one region that I had found interactive with a CDK inhibitor protein p21.(04:17):And so, I asked my boss, what do you think about the possibility this cyclin could have evolved from cyclin D but now mutated its surface residues in a specific area so that it can't be inhibited by any of the control proteins in the mammalian cell cycle? He said, it's a great idea, Charlie, give it a shot. And it worked. And then six months later, we got a Nature paper. And that for me was like, I cannot tell you how exciting, not the Nature paper so much as the discovery that you were the first person in the world to ever see this beautiful aspect of evolutionary biology at play and how this cyclin had adapted to just drive the cell cycle without being inhibited. For me, just, I mean, it was like a dream come true, and I never experienced anything like it before, and I guess it's sizes the equivalent to me of a class A drug. You get such a buzz out of it and over the years you sort of long for that to happen again. And occasionally it does, and it's just a wonderful profession.Eric Topol (05:20):Well, I thought that it was such a great story because here you were about to fail. I mean literally fail, and you really were able to turn it around and it should give hope to everybody working in science out there that they could just be right around the corner from a significant discovery.Charles Swanton (05:36):I think what doesn't break you makes you stronger. You just got to plow on if you love it enough, you'll find a way forward eventually, I hope.Tracing the Evolution of Cancer (TRACERx)Eric Topol (05:44):Yeah, no question about that. Now, some of your recent contributions, I mean, it's just amazing to me. I just try to keep up with the literature just keeping up with you.Charles Swanton (05:58):Eric, it's sweet of you. The first thing to say is it's not just me. This is a big community of lung cancer researchers we have thanks to Cancer Research UK funded around TRACERx and the lung cancer center. Every one of my papers has three corresponding authors, multiple co-first authors that all contribute in this multidisciplinary team to the sort of series of small incremental discoveries. And it's absolutely not just me. I've got an amazing team of scientists who I work with and learn from, so it's sweet to give me the credit.Eric Topol (06:30):I think what you're saying is really important. It is a team, but I think what I see through it all is that you're an inspiration to the team. You pull people together from all over the world on these projects and it's pretty extraordinary, so that's what I would say.Charles Swanton (06:49):The lung community, Eric, the lung cancer community is just unbelievably conducive to collaboration and advancing understanding of the disease together. It's just such a privilege to be working in this field. I know that sounds terribly corny, but it is true. I don't think I recall a single email to anybody where I've asked if we can collaborate where they've said, no, everybody wants to help. Everybody wants to work together on this challenge. It's just such an amazing field to be working in.Eric Topol (07:19):Yeah. Well I was going to ask you about that. And of course you could have restricted your efforts or focused on different cancers. What made you land in lung cancer? Not that that's only part of what you're working on, but that being the main thing, what drew you to that area?Charles Swanton (07:39):So I think the answer to your question is back in 2008 when I was looking for a niche, back then it was lung cancer was just on the brink of becoming an exciting place to work, but back then nobody wanted to work in that field. So there was a chair position in thoracic oncology and precision medicine open at University College London Hospital that had been open, as I understand it for two years. And I don't think anybody had applied. So I applied and because I was the only one, I got it and the rest is history.(08:16):And of course that was right at the time when the IPASS draft from Tony Mok was published and was just a bit after when the poster child of EGFR TKIs and EGFR mutant lung cancer had finally proven that if you segregate that population of patients with EGFR activating mutation, they do incredibly well on an EGFR inhibitor. And that was sort of the solid tumor poster child along with Herceptin of precision medicine, I think. And you saw the data at ASCO this week of Lorlatinib in re-arranged lung cancer. Patients are living way beyond five years now, and people are actually talking about this disease being more like CML. I mean, it's extraordinary the progress that's been made in the last two decades in my short career.Eric Topol (09:02):Actually, I do want to have you put that in perspective because it's really important what you just mentioned. I was going to ask you about this ASCO study with the AKT subgroup. So the cancer landscape of the lung has changed so much from what used to be a disease of cigarette smoking to now one of, I guess adenocarcinoma, non-small cell carcinoma, not related to cigarettes. We're going to talk about air pollution in a minute. This group that had, as you say, 60 month, five year plus survival versus what the standard therapy was a year plus is so extraordinary. But is that just a small subgroup within small cell lung cancer?Charles Swanton (09:48):Yes, it is, unfortunately. It's just a small subgroup. In our practice, probably less than 1% of all presentations often in never smokers, often in female, never smokers. So it is still in the UK at least a minority subset of adenocarcinomas, but it's still, as you rightly say, a minority of patients that we can make a big difference to with a drug that's pretty well tolerated, crosses the blood-brain barrier and prevents central nervous system relapse and progression. It really is an extraordinary breakthrough, I think. But that said, we're also seeing advances in smoking associated lung cancer with a high mutational burden with checkpoint inhibitor therapy, particularly in the neoadjuvant setting now prior to surgery. That's really, really impressive indeed. And adjuvant checkpoint inhibitor therapies as well as in the metastatic setting are absolutely improving survival times and outcomes now in a way that we couldn't have dreamt of 15 years ago. We've got much more than just platinum-based chemo is basically the bottom line now.Revving Up ImmunotherapyEric Topol (10:56):Right, right. Well that actually gets a natural question about immunotherapy also is one of the moving parts actually just amazing to me how that's really, it's almost like we're just scratching the surface of immunotherapy now with checkpoint inhibitors because the more we get the immune system revved up, the more we're seeing results, whether it's with vaccines or CAR-T, I mean it seems like we're just at the early stages of getting the immune system where it needs to be to tackle the cancer. What's your thought about that?Charles Swanton (11:32):I think you're absolutely right. We are, we're at the beginning of a very long journey thanks to Jim Allison and Honjo. We've got CTLA4 and PD-1/PDL-1 axis to target that's made a dramatic difference across multiple solid tumor types including melanoma and lung cancer. But undoubtedly, there are other targets we've seen LAG-3 and melanoma and then we're seeing new ways, as you rightly put it to mobilize the immune system to target cancers. And that can be done through vaccine based approaches where you stimulate the immune system against the patient's specific mutations in their cancer or adoptive T-cell therapies where you take the T-cells out of the tumor, you prime them against the mutations found in the tumor, you expand them and then give them back to the patient. And colleagues in the US, Steve Rosenberg and John Haanen in the Netherlands have done a remarkable job there in the context of melanoma, we're not a million miles away from European approvals and academic initiated manufacturing of T-cells for patients in national health systems like in the Netherlands.(12:50):John Haanen's work is remarkable in that regard. And then there are really spectacular ways of altering T-cells to be able to either migrate to the tumor or to target specific tumor antigens. You mentioned CAR-T cell therapies in the context of acute leukemia, really extraordinary developments there. And myeloma and diffuse large B-cell lymphoma as well as even in solid tumors are showing efficacy. And I really am very excited about the future of what we call biological therapies, be it vaccines, an antibody drug conjugates and T-cell therapies. I think cancer is a constantly adapting evolutionary force to be reckoned with what better system to combat it than our evolving immune system. It strikes me as being a future solution to many of these refractory cancers we still find difficult to treat.Eric Topol (13:48):Yeah, your point is an interesting parallel how the SARS-CoV-2 virus is constantly mutating and becoming more evasive as is the tumor in a person and the fact that we can try to amp up the immune system with these various means that you just were reviewing. You mentioned the other category that's very hot right now, which is the antibody drug conjugates. Could you explain a bit about how they work and why you think this is an important part of the future for cancer?Antibody-Drug ConjugatesCharles Swanton (14:26):That's a great question. So one of the challenges with chemotherapy, as you know, is the normal tissue toxicity. So for instance, neutropenia, hair loss, bowel dysfunction, diarrhea, epithelial damage, essentially as you know, cytotoxics affect rapidly dividing tissues, so bone marrow, epithelial tissues. And because until relatively recently we had no way of targeting chemotherapy patients experienced side effects associated with them. So over the last decade or so, pioneers in this field have brought together this idea of biological therapies linked with chemotherapy through a biological linker. And so one poster chart of that would be the drug T-DXd, which is essentially Herceptin linked to a chemotherapy drug. And this is just the most extraordinary drug that obviously binds the HER2 receptor, but brings the chemotherapy and proximity of the tumor. The idea being the more drug you can get into the tumor and the less you're releasing into normal tissue, the more on tumor cytotoxicity you'll have and the less off tumor on target normal tissue side effects you'll have. And to a large extent, that's being shown to be the case. That doesn't mean they're completely toxicity free, they're not. And one of the side effects associated with these drugs is pneumonitis.(16:03):But that said, the efficacy is simply extraordinary. And for example, we're having to rewrite the rule books if you like, I think. I mean I'm not a breast cancer physician, I used to be a long time ago, but back in the past in the early 2000s, there was HER2 positive breast cancer and that's it. Now they're talking about HER2 low, HER2 ultra-low, all of which seem to in their own way be sensitive to T-DXd, albeit to a lower extent than HER2 positive disease. But the point is that there doesn't seem to be HER2 completely zero tumor group in breast cancer. And even the HER2-0 seem to benefit from T-DXd to an extent. And the question is why? And I think what people are thinking now is it's a combination of very low cell service expression of HER2 that's undetectable by conventional methods like immunohistochemistry, but also something exquisitely specific about the way in which HER2 is mobilized on the membrane and taken back into the cell. That seems to be specific to the breast cancer cell but not normal tissue. So in other words, the antibody drug conjugate binds the tumor cell, it's thought the whole receptor's internalized into the endosome, and that's where the toxicity then happens. And it's something to do with the endosomal trafficking with the low level expression and internalization of the receptor. That may well be the reason why these HER2 low tumors are so sensitive to this beautiful technology.Eric Topol (17:38):Now I mean it is an amazing technology in all these years where we just were basically indiscriminately trying to kill cells and hoping that the cancer would succumb. And now you're finding whether you want to call it a carry or vector or Trojan horse, whatever you want to call it, but do you see that analogy of the HER2 receptor that's going to be seen across the board in other cancers?Charles Swanton (18:02):That's the big question, Eric. I think, and have we just lucked out with T-DXd, will we find other T-DXd like ADCs targeting other proteins? I mean there are a lot of ADCs being developed against a lot of different cell surface proteins, and I think the jury's still out. I'm confident we will, but we have to bear in mind that biology is a fickle friend and there may be something here related to the internalization of the receptor in breast cancer that makes this disease so exquisitely sensitive. So I think we just don't know yet. I'm reasonably confident that we will find other targets that are as profoundly sensitive as HER2 positive breast cancer, but time will tell.Cancer, A Systemic DiseaseEric Topol (18:49):Right. Now along these lines, well the recent paper that you had in Cell, called embracing cancer complexity, which we've talking about a bit, in fact it's kind of those two words go together awfully well, but hallmarks of systemic disease, this was a masterful review, as you say with the team that you led. But can you tell us about what's your main perspective about this systemic disease? I mean obviously there's been the cancer is like cardiovascular and cancers like this or that, but here you really brought it together with systemic illness. What can you say about that?Charles Swanton (19:42):Well, thanks for the question first of all, Eric. So a lot of this comes from some of my medical experience of treating cancer and thinking to myself over the years, molecular biology has had a major footprint on advances in treating the disease undoubtedly. But there are still aspects of medicine where molecular biology has had very little impact, and often that is in areas of suffering in patients with advanced disease and cancer related to things like cancer cachexia, thrombophilia. What is the reason why patients die blood clots? What is the reason patients die of cancer at all? Even a simple question like that, we don't always know the answer to, on death certificates, we write metastatic disease as a cause of cancer death, but we have patients who die with often limited disease burden and no obvious proximal cause of death sometimes. And that's very perplexing, and we need to understand that process better.(20:41):And we need to understand aspects like cancer pain, for example, circadian rhythms affect biological sensitivity of cancer cells to drugs and what have you. Thinking about cancer rather than just sort of a single group of chaotically proliferating cells to a vision of cancer interacting both locally within a microenvironment but more distantly across organs and how organs communicate with the cancer through neuronal networks, for example, I think is going to be the next big challenge by setting the field over the next decade or two. And I think then thinking about more broadly what I mean by embracing complexity, I think some of that relates to the limitations of the model systems we use, trying to understand inter-organ crosstalk, some of the things you cover in your beautiful Twitter reviews. (←Ground Truths link) I remember recently you highlighted four publications that looked at central nervous system, immune cell crosstalk or central nervous system microbiome crosstalk. It's this sort of long range interaction between organs, between the central nervous system and the immune system and the cancer that I'm hugely interested in because I really think there are vital clues there that will unlock new targets that will enable us to control cancers more effectively if we just understood these complex networks better and had more sophisticated animal model systems to be able to interpret these interactions.Eric Topol (22:11):No, it's so important what you're bringing out, the mysteries that still we have to deal with cancer, why patients have all these issues or dying without really knowing what's happened no less, as you say, these new connects that are being discovered at a remarkable pace, as you mentioned, that ground truths. And also, for example, when I spoke with Michelle Monje, she's amazing on the cancer, where hijacking the brain cells and just pretty extraordinary things. Now that gets me to another line of work of yours. I mean there are many, but the issue of evolution of the tumor, and if you could put that in context, a hot area that's helping us elucidate these mechanisms is known as spatial omics or spatial biology. This whole idea of being able to get the spatial temporal progression through single cell sequencing and single cell nuclei, all the single cell omics. So if you could kind of take us through what have we learned with this technique and spatial omics that now has changed or illuminated our understanding of how cancer evolves?Charles Swanton (23:37):Yeah, great question. Well, I mean I think it helps us sort of rewind a bit and think about evolution in general. Genetic selection brought about by diverse environments and environmental pressures that force evolution, genetic evolution, and speciation down certain evolutionary roots. And I think one can think about cancers in a similar way. They start from a single cell and we can trace the evolutionary paths of cancers by single cell analysis as well as bulk sequencing of spatially separated tumor regions to be able to reconstruct their subclones. And that's taught us to some extent, what are the early events in tumor evolution? What are the biological mechanisms driving branched evolution? How does genome instability begin in tumors? And we found through TRACERx work, whole genome doubling is a major route through to driving chromosome instability along with mutagenic enzymes like APOBEC that drive both mutations and chromosomal instability.(24:44):And then that leads to a sort of adaptive radiation in a sense, not dissimilar to I guess the Cambrian explosion of evolutionary opportunity upon which natural selection can act. And that's when you start to see the hallmarks of immune evasion like loss of HLA, the immune recognition molecules that bind the neoantigens or even loss of the neoantigens altogether or mutation of beta 2 microglobulin that allow the tumor cells to now evolve below the radar, so to speak. But you allude to the sort of spatial technologies that allow us to start to interpret the microenvironments as well. And that then tells us what the evolutionary pressures are upon the tumor. And we're learning from those spatial technologies that these environments are incredibly diverse, actually interestingly seem to be converging on one important aspect I'd like to talk to you a little bit more about, which is the myeloid axis, which is these neutrophils, macrophages, et cetera, that seem to be associated with poor outcome and that will perhaps talk about pollution in a minute.(25:51):But I think they're creating a sort of chronic inflammatory response that allows these early nascent tumor cells to start to initiate into frankly tumor invasive cells and start to grow. And so, what we're seeing from these spatial technologies in lung cancer is that T-cells, predatory T-cells, force tumors to lose their HLA molecules and what have you to evade the immune system. But for reasons we don't understand, high neutrophil infiltration seems to be associated with poor outcome, poor metastasis free survival. And actually, those same neutrophils we've recently found actually even tracked to the metastasis sites of metastasis. So it's almost like this sort of symbiosis between the myeloid cells and the tumor cells in their biology and growth and progression of the tumor cells.Eric Topol (26:46):Yeah, I mean this white cell story, this seems to be getting legs and is relatively new, was this cracked because of the ability to do this type of work to in the past everything was, oh, it's cancer's heterogeneous and now we're getting pinpoint definition of what's going on.Charles Swanton (27:04):I think it's certainly contributed, but it's like everything in science, Eric, when you look back, there's evidence in the literature for pretty much everything we've ever discovered. You just need to put the pieces together. And I mean one example would be the neutrophil lymphocyte ratio in the blood as a hallmark of outcome in cancers and to checkpoint inhibitor blockade, maybe this begins to explain it, high neutrophils, immune suppressive environment, high neutrophils, high macrophages, high immune suppression, less benefit from checkpoint inhibitor therapy, whereas you want lymphocyte. So I think there are biomedical medical insights that help inform the biology we do in the lab that have been known for decades or more. And certainly the myeloid M2 axis in macrophages and what have you was known about way before these spatial technologies really came to fruition, I think.The Impact of Air PollutionEric Topol (28:01):Yeah. Well you touched on this about air pollution and that's another dimension of the work that you and your team have done. As you well know, there was a recent global burden of disease paper in the Lancet, which has now said that air pollution with particulate matter 2.5 less is the leading cause of the burden of disease in the world now.Charles Swanton (28:32):What did you think of that, Eric?Eric Topol (28:34):I mean, I was blown away. Totally blown away. And this is an era you've really worked on. So can you put it in perspective?Charles Swanton (28:42):Yeah. So we got into this because patients of mine, and many of my colleagues would ask the same question, I've never smoked doctor, I'm healthy. I'm in my mid 50s though they're often female and I've got lung cancer. Why is that doctor? I've had a good diet, I exercise, et cetera. And we didn't really have a very good answer for that, and I don't want to pretend for a minute we solved the whole problem. I think hopefully we've contributed to a little bit of understanding of why this may happen. But that aside, we knew that there were risk factors associated with lung cancer that included air pollution, radon exposure, of course, germline genetics, we mustn't forget very important germline variation. And I think there is evidence that all of them are associated with lung cancer risk in different ways. But we wanted to look at air pollution, particularly because there was an awful lot of evidence, several meta-analysis of over half a million individuals showing very convincingly with highly significant results that increasing PM 2.5 micron particulate levels were associated with increased risk of lung cancer.(29:59):To put that into perspective, where you are on the west coast of the US, it's relatively unpolluted. You would be talking about maybe five micrograms per meter cubed of PM2.5 in a place like San Diego or Western California, assuming there aren't any forest fires of course. And we estimate that that would translate to about, we think it's about one extra case of never smoking lung cancer per hundred thousand of the population per year per one microgram per meter cube rise in the pollution levels. So if you go to Beijing for example, on a bad day, the air pollution levels could be upwards of a hundred micrograms per meter cubed because there are so many coal fired power stations in China partly. And there I think the risk is considerably higher. And that's certainly what we've seen in the meta-analyses in our limited and relatively crude epidemiological analyses to be the case.(30:59):So I think the association was pretty certain, we were very confident from people's prior publications  this was important. But of course, association is not causation. So we took a number of animal models and showed that you could promote lung cancer formation in four different oncogene driven lung cancer models. And then the question is how, does air pollution stimulate mutations, which is what I initially thought it would do or something else. It turns out we don't see a significant increase in exogenous like C to A carcinogenic mutations. So that made us put our thinking caps on. And I said to you earlier, often all these discoveries have been made before. Well, Berenblum in 1947, first postulated that actually tumors are initiated through a two-step process, which we now know involves a sort of pre initiated cell with a mutation in that in itself is not sufficient to cause cancer.(31:58):But on top of that you need an inflammatory stimulus. So the question was then, well, okay, is inflammation working here? And we found that there was an interleukin-1 beta axis. And what happens is that the macrophages come into the lung on pollution exposure, engulf phagocytose the air pollutants, and we think what's happening is the air pollutants are puncturing membranes in the lung. That's what we think is happening. And interleukin-1 beta preformed IL-1 beta is being released into the extracellular matrix and then stimulating pre-initiated cells stem cells like the AT2 cells with an activating EGFR mutation to form a tumor. But the EGFR mutation alone is not sufficient to form tumors. It's only when you have the interleukin-1 beta and the activated mutation that a tumor can start.(32:49):And we found that if we sequence normal lung tissue in a healthy adult 60-year-old adult, we will find about half of biopsies will have an activating KRAS mutation in normal tissue, and about 15% will have an activating mutation in EGFR in histologically normal tissue with nerve and of cancer. In fact, my friend and colleague who's a co-author on the paper, James DeGregori, who you should speak to in Colorado, fascinating evolutionary cancer biologists estimates that in a healthy 60-year-old, there are a hundred billion cells in your body that harbor an oncogenic mutation. So that tells you that at the cellular level, cancer is an incredibly rare event and almost never happens. I mean, our lifetime risk of cancer is perhaps one in two. You covered that beautiful pancreas paper recently where they estimated that there may be 80 to 100 KRAS mutations in a normal adult pancreas, and yet our lifetime risk of pancreas cancer is one in 70. So this tells you that oncogenic mutations are rarely sufficient to drive cancer, so something else must be happening. And in the context of air pollution associated lung cancer, we think that's inflammation driven by these white cells, these myeloid cells, the macrophages.Cancer BiomarkersEric Topol (34:06):No, it makes a lot of sense. And this, you mentioned the pancreas paper and also what's going in the lung, and it seems like we have this burden of all you need is a tipping point and air pollution seems to qualify, and you seem to be really in the process of icing the mechanism. And like I would've thought it was just mutagenic and it's not so simple, right? But that gets me to this is such an important aspect of cancer, the fact that we harbor these kind of preconditions. And would you think that cancer takes decades to actually manifest most cancers, or do we really have an opportunity here to be able to track whether it's through blood or other biomarkers? Another area you've worked on a lot whereby let's say you could define people at risk for polygenic risk scores or various cancers or genome sequencing for predisposition genes, whatever, and you could monitor in the future over the course of those high-risk people, whether they were starting to manifest microscopic malignancy. Do you have any thoughts about how long it takes for the average person to actually manifest a typical cancer?Charles Swanton (35:28):That's a cracking question, and the answer is we've got some clues in various cancers. Peter Campbell would be a good person to speak to. He estimates that some of the earliest steps in renal cancer can occur in adolescence. We've had patients who gave up smoking 30 or so years ago where we can still see the clonal smoking mutations in the trunk of the tumor's evolutionary tree. So the initial footprints of the cancer are made 30 years before the cancer presents. That driver mutation itself may also be a KRAS mutation in a smoking cigarette context, G12C mutation. And those mutations can precede the diagnosis of the disease by decades. So the earliest steps in cancer evolution can occur, we think can precede diagnoses by a long time. So to your point, your question which is, is there an opportunity to intervene? I'm hugely optimistic about this actually, this idea of molecular cancer prevention.An Anti-Inflammatory Drug Reduces Fatal Cancer and Lung Cancer(36:41):How can we use data coming out of various studies in the pancreas, mesothelioma, lung, et cetera to understand the inflammatory responses? I don't think we can do very much about the mutations. The mutations unfortunately are a natural consequence of aging. You and I just sitting here talking for an hour will have accumulated multiple mutations in our bodies over that period, I'm afraid and there's no escaping it. And right now there's not much we can do to eradicate those mutant clones. So if we take that as almost an intractable problem, measuring them is hard enough, eradicating them is even harder. And then we go back to Berenblum in 1947 who said, you need an inflammatory stimulus. Well, could we do something about the inflammation and dampen down the inflammation? And of course, this is why we got so excited about IL-1 beta because of the CANTOS trial, which you may remember in 2017 from Ridker and colleagues showed that anti IL-1 beta used as a mechanism of preventing cardiovascular events was associated with a really impressive dose dependent reduction in new lung cancer primaries.(37:49):Really a beautiful example of cancer prevention in action. And that data weren't just a coincidence. The FDA mandated Novartis to collect the solid tumor data and the P-values are 0.001. I mean it's very highly significant dose dependent reduction in lung cancer incidents associated with anti IL-1 beta. So I think that's really the first clue in my mind that something can be done about this problem. And actually they had five years of follow-up, Eric. So that's something about that intervening period where you can treat and then over time see a reduction in new lung cancers forming. So I definitely think there's a window of opportunity here.Eric Topol (38:31):Well, what you're bringing up is fascinating here because this trial, which was a cardiology trial to try to reduce heart attacks, finds a reduction in cancer, and it's been lost. It's been buried. I mean, no one's using this therapy to prevent cancer between ratcheting up the immune system or decreasing inflammation. We have opportunities that we're not even attempting. Are there any trials that are trying to do this sort of thing?Charles Swanton (39:02):So this is the fundamental problem. Nobody wants to invest in prevention because essentially you are dealing with well individuals. It's like the vaccine challenge all over again. And the problem is you never know who you are benefiting. There's no economic model for it. So pharma just won't touch prevention with a barge pole right now. And that's the problem. There's no economic model for it. And yet the community, all my academic colleagues are crying out saying, this has got to be possible. This has got to be possible. So CRUK are putting together a group of like-minded individuals to see if we can do something here and we're gradually making progress, but it is tough.Eric Topol (39:43):And it's interesting that you bring that up because for GRAIL, one of the multicenter cancer early detection companies, they raised billions of dollars. And in fact, their largest trial is ongoing in the UK, but they haven't really focused on high-risk people. They just took anybody over age 50 or that sort of thing. But that's the only foray to try to reboot how we or make an early microscopic diagnosis of cancer and track people differently. And there's an opportunity there. You've written quite a bit on you and colleagues of the blood markers being able to find a cancer where well before, in fact, I was going to ask you about that is, do you think there's people that are not just having all these mutations every minute, every hour, but that are starting to have the early seeds of cancer, but because their immune system then subsequently kicks in that they basically kind of quash it for that period of time?Charles Swanton (40:47):Yeah, I do think that, I mean, the very fact that we see these sort of footprints in the tumor genome of immune evasion tells you that the immune system's having a very profound predatory effect on evolving tumors. So I do think it's very likely that there are tumors occurring that are suppressed by the immune system. There is a clear signature, a signal of negative selection in tumors where clones have been purified during their evolution by the immune system. So I think there's pretty strong evidence for that now. Obviously, it's very difficult to prove something existed when it doesn't now exist, but there absolutely is evidence for that. I think it raises the interesting question of immune system recognizes mutations and our bodies are replete with mutations as we were just discussing. Why is it that we're not just a sort of epithelial lining of autoimmunity with T-cells and immune cells everywhere? And I think what the clever thing about the immune system is it's evolved to target antigens only when they get above a certain burden. Otherwise, I think our epithelial lining, our skin, our guts, all of our tissues will be just full of T-cells eating away our normal clones.(42:09):These have to get to a certain size for antigen to be presented at a certain level for the immune system to recognize it. And it's only then that you get the immune predation occurring.Forever Chemicals and Microplastics Eric Topol (42:20):Yeah, well, I mean this is opportunities galore here. I also wanted to extend the air pollution story a bit. Obviously, we talked about particulate matter and there's ozone and nitric NO2, and there's all sorts of other air pollutants, but then there's also in the air and water these forever chemicals PFAS for abbreviation, and they seem to be incriminated like air pollution. Can you comment about that?Charles Swanton (42:55):Well, I can comment only insofar as to say I'm worried about the situation. Indeed, I'm worried about microplastics actually, and you actually cover that story as well in the New England Journal, the association of microplastics with plaque rupture and atheroma. And indeed, just as in parenthesis, I wanted to just quickly say we currently think the same mechanisms that are driving lung cancer are probably responsible for atheroma and possibly even neurodegenerative disease. And essentially it all comes down to the macrophages and the microglia becoming clogged up with these pollutants or environmental particulars and releasing chronic inflammatory mediators that ultimately lead to disease. And IL-1 beta being one of those in atheroma and probably IL-6 and TNF in neurodegenerative disease and what have you. But I think this issue that you rightly bring up of what is in our environment and how does it cause pathology is really something that epidemiologists have spent a lot of time focusing on.(43:56):But actually in terms of trying to move from association to causation, we've been, I would argue a little bit slow biologically in trying to understand these issues. And I think that is a concern. I mean, to give you an example, Allan Balmain, who works at UCSF quite close to you, published a paper in 2020 showing that 17 out of 20 environmental carcinogens IARC carcinogens class one carcinogens cause tumors in rodent models without driving mutations. So if you take that to a logical conclusion, in my mind, what worries me is that many of the sort of carcinogen assays are based on driving mutagenesis genome instability. But if many carcinogen aren't driving DNA mutagenesis but are still driving cancer, how are they doing it? And do we actually have the right assays to interpret safety of new chemical matter that's being introduced into our environment, these long-lived particles that we're breathing in plastics, pollutants, you name it, until we have the right biological assays, deeming something to be safe I think is tricky.Eric Topol (45:11):Absolutely. And I share your concerns on the nanoplastic microplastic story, as you well know, not only have they been seen in arteries that are inflamed and in blood clots and in various tissues, have they been seen so far or even looked for within tumor tissue?Charles Swanton (45:33):Good question. I'm not sure they have. I need to check. What I can tell you is we've been doing some experiments in the lab with fluorescent microplastics, 2.5 micron microplastics given inhaled microplastics. We find them in every mouse organ a week after. And these pollutants even get through into the brain through the olfactory bulb we think.Charles Swanton (45:57):Permeate every tissue, Eric.Eric Topol (45:59):Yeah, no, this is scary because here we are, we have these potentially ingenious ways to prevent cancer in the future, but we're chasing our tails by not doing anything to deal with our environment.Charles Swanton (46:11):I think that's right. I totally agree. Yeah.Eric Topol (46:15):So I mean, I can talk to you for the rest of the day, but I do want to end up with a topic that we have mutual interest in, which is AI. And also along with that, when you mentioned about aging, I'd like to get your views on these two, how do you see AI fitting into the future of cancer? And then the more general topic is, can we actually at some point modulate the biologic aging process with or without help with from AI? So those are two very dense questions, but maybe you can take us through them.Charles Swanton (46:57):How long have we got?Eric Topol (46:59):Just however long you have.A.I. and CancerCharles Swanton (47:02):AI and cancer. Well, AI and medicine actually in general, whether it's biomedical research or medical care, has just infinite potential. And I'm very, very excited about it. I think what excites me about AI is it's almost the infinite possibilities to work across scale. Some of the challenges we raised in the Cell review that you mentioned, tackling, embracing complexity are perfectly suited for an AI problem. Nonlinear data working, for instance in our fields with CT imaging, MRI imaging, clinical outcome data, blood parameters, genomics, transcriptomes and proteomes and trying to relate this all into something that's understandable that relates to risk of disease or potential identification of a new drug target, for example. There are numerous publications that you and others have covered that allude to the incredible possibilities there that are leading to, for instance, the new identification of drug targets. I mean, Eli Van Allen's published some beautiful work here and in the context of prostate cancer with MDM4 and FGF receptor molecules being intimately related to disease biology.(48:18):But then it's not just that, not just drug target identification, it's also going all the way through to the clinic through drug discovery. It's how you get these small molecules to interact with oncogenic proteins and to inhibit them. And there are some really spectacular developments going on in, for instance, time resolved cryo-electron microscopy, where in combination with modeling and quantum computing and what have you, you can start to find pockets emerging in mutant proteins, but not the wild type ones that are druggable. And then you can use sort of synthetic AI driven libraries to find small molecules that will be predicted to bind these transiently emerging pockets. So it's almost like AI is primed to help at every stage in scientific investigation from the bench all the way through to the bedside. And there are examples all the way through there in the literature that you and others have covered in the last few years. So I could not be more excited about that.Eric Topol (49:29):I couldn't agree with you more. And I think when we get to multimodal AI at the individual level across all their risks for conditions in their future, I hope someday will fulfill that fantasy of primary prevention. And that is getting me to this point that I touched on because I do think they interact to some degree AI and then will we ever be able to have an impact on aging? Most people conflate this because what we've been talking about throughout the hour has been age-related diseases, that is cancer, for example, and cardiovascular and neurodegenerative, which is different than changing aging per se, body wide aging. Do you think we'll ever changed body wide aging?Charles Swanton (50:18):Wow, what a question. Well, if you'd asked me 10 years ago, 15 years ago, do you think we'll ever cure melanoma in my lifetime, I'd have said definitely not. And now look where we are. Half of patients with melanoma, advanced melanoma, even with brain metastasis curd with combination checkpoint therapy. So I never say never in biology anymore. It always comes back to bite you and prove you wrong. So I think it's perfectly possible.Charles Swanton (50:49):We have ways to slow down the aging process. I guess the question is what will be the consequences of that?Eric Topol (50:55):That's what I was going to ask you, because all these things like epigenetic reprogramming and senolytic drugs, and they seem to at least pose some risk for cancer.Charles Swanton (51:09):That's the problem. This is an evolutionary phenomenon. It's a sort of biological response to the onslaught of these malignant cells that are potentially occurring every day in our normal tissue. And so, by tackling one problem, do we create another? And I think that's going to be the big challenge over the next 50 years.Eric Topol (51:31):Yeah, and I think your point about the multi-decade challenge, because if you can promote healthy aging without any risk of cancer, that would be great. But if the tradeoff is close, it's not going to be very favorable. That seems to be the main liability of modulation aging through many of the, there's many shots on goal here, of course, as you well know. But they do seem to pose that risk in general.Charles Swanton (51:58):I think that's right. I think the other thing is, I still find, I don't know if you agree with me, but it is an immense conundrum. What is the underlying molecular basis for somatic aging, for aging of normal tissues? And it may be multifactorial, it may not be just one answer to that question. And different tissues may age in different ways. I don't know. It's a fascinating area of biology, but I think it really needs to be studied more because as you say, it underpins all of these diseases we've been talking about today, cardiovascular, neurodegeneration, cancer, you name it. We absolutely have to understand this. And actually, the more I work in cancer, the more I feel like actually what I'm working on is aging.(52:48):And this is something that James DeGregori and I have discussed a lot. There's an observation that in medicine around patients with alpha-1 antitrypsin deficiency who are at higher risk of lung cancer, but they're also at high risk of COPD, and we know the associations of chronic obstructive pulmonary disease with lung cancer risk. And one of the theories that James had, and I think this is a beautiful idea, actually, is as our tissues age, and COPD is a reflection of aging, to some extent gone wrong. And as our tissues age, they become less good at controlling the expansion of these premalignant clones, harboring, harboring oncogenic mutations in normal tissue. And as those premalignant clones expand, the substrate for evolution also expands. So there's more likely to be a second and third hit genetically. So it may be by disrupting the extracellular matrices through inflammation that triggers COPD through alpha-1 antitrypsin deficiency or smoking, et cetera, you are less effectively controlling these emergent clones that just expand with age, which I think is a fascinating idea actually.Eric Topol (54:01):It really is. Well, I want to tell you, Charlie, this has been the most fascinating, exhilarating discussion I've ever had on cancer. I mean, really, I am indebted to you because not just all the work you've done, but your ability to really express it, articulate it in a way that hopefully everyone can understand who's listening or reading the transcript. So we'll keep following what you're doing because you're doing a lot of stuff. I can't thank you enough for joining me today, and you've given me lots of things to think about. I hope the people that are listening or reading feel the same way. I mean, this has been so mind bending in many respects. We're indebted to you.Charles Swanton (54:49):Well, we all love reading your Twitter feeds. Keep them coming. It helps us keep a broader view of medicine and biological research, not just cancer, which is why I love it so much.******************************************The Ground Truths newsletters and podcasts are all free, open-access, without ads.Please share this post/podcast with your friends and network if you found it informativeVoluntary paid subscriptions all go to support Scripps Research. Many thanks for that—they greatly helped fund our summer internship programs for 2023 and 2024.Thanks to my producer Jessica Nguyen and Sinjun Balabanoff tor audio and video support at Scripps Research.Note: you can select preferences to receive emails about newsletters, podcasts, or all I don't want to bother you with an email for content that you're not interested in. Get full access to Ground Truths at erictopol.substack.com/subscribe

AI chipmaker Nvidia's value has overtaken Apple and surpassed three trillion dollars - meaning it's now the world's second most valuable company.James Lee, clinician scientist group leader at the Francis Crick Institute, tells Tech & Science Daily about his research which has discovered a major cause of inflammatory bowel disease. Boeing finally launches its long-delayed astronaut capsule.Also in this episode:Leak claims the new Apple iPhone 16 Pro Max will have a record-breaking design Energy drinks ‘may trigger dangerous condition in people with heart disease'Do you know what your fridge temperature should really be? Because a lot of us don't according to a studyBrits have an average of 339 'outtakes' on their phones Follow us on X or on Threads. Hosted on Acast. See acast.com/privacy for more information.

Nobel Prize laureate Sir Paul Nurse wants science, not politics, to guide the debate surrounding climate change. But how do you convince the denialists? Babita Sharma takes us through the evolving strategies of those who claim climate change isn't real, and speaks to two young people who are trying to make a difference. UK climate activist Phoebe L Hanson founded Teach the Teacher, which gives school children the resources to engage with their teachers on climate change. Ugandan Nyombi Morris set up a non-profit organisation, Earth Volunteers, to mobilise young people like him who wanted to promote the fight against the climate crisis.This content was created as a co-production between Nobel Prize Outreach and the BBC. Image credit: Francis Crick Institute

Joe Roman is a conservation biologist and marine ecologist fascinated with the natural processes that go on within animal biology and how those in turn shape the natural world around us. His new book is Eat, Poop, Die, which as the title suggests, takes a no-nonsense look at how the biology of individual living things on planet Earth forms an integral part of the chain of natural ecology that keeps the world working. Speaking to Roman for this episode is molecular biologist and science communicator Dr Gunes Taylor, who is postdoctoral research scientist at the Francis Crick Institute. We are sponsored by Indeed. Go to Indeed.com/IS for £100 sponsored credit. If you'd like to become a Member and get access to all of our longer form interviews and Members-only content, just visit intelligencesquared.com/membership to find out more. For £4.99 per month you'll also receive: - Full-length and ad-free Intelligence Squared episodes, wherever you get your podcasts - Bonus Intelligence Squared podcasts, curated feeds and members exclusive series - 15% discount on livestreams and in-person tickets for all Intelligence Squared events - Our member-only newsletter The Monthly Read, sent straight to your inbox ... Or Subscribe on Apple for £4.99: - Full-length and ad-free Intelligence Squared podcasts - Bonus Intelligence Squared podcasts, curated feeds and members exclusive series ... Already a subscriber? Thank you for supporting our mission to foster honest debate and compelling conversations! Visit intelligencesquared.com to explore all your benefits including ad-free podcasts, exclusive bonus content and early access. ... Subscribe to our newsletter here to hear about our latest events, discounts and much more. https://www.intelligencesquared.com/newsletter-signup/ Learn more about your ad choices. Visit podcastchoices.com/adchoices

The spring 2024 edition of Unearthed! concludes with books and letters, fashion and cosmetics, medicine, shipwrecks, and the assorted finds that are categorized as potpourri. Research: Abdallah, Hannah. “The first Neolithic boats in the Mediterranean.” EurekAlert. 3/20/2024. https://www.eurekalert.org/news-releases/1037843 Adam Rohrlach, Cases of trisomy 21 and trisomy 18 among historic and prehistoric individuals discovered from ancient DNA, Nature Communications (2024). DOI: 10.1038/s41467-024-45438-1. www.nature.com/articles/s41467-024-45438-1 Addley, Esther. “‘Flat-packed furniture for the next life': Roman funerary bed found in London.” The Guardian. 2/5/2024. https://www.theguardian.com/science/2024/feb/05/flat-packed-furniture-for-the-next-life-roman-funerary-bed-found-in-london Alberge, Dalya. “‘Incredibly rare' discovery reveals bedbugs came to Britain with the Romans.” The Guardian. 2/3/2024. https://www.theguardian.com/environment/2024/feb/03/incredibly-rare-discovery-reveals-bedbugs-came-to-britain-with-the-romans Anderson, Sonja. “Another Mysterious Roman Dodecahedron Has Been Unearthed in England.” Smithsonian. 1/22/2024. https://www.smithsonianmag.com/smart-news/another-of-ancient-romes-mysterious-12-sided-objects-has-been-found-in-england-180983632/ Anderson, Sonja. “Bodies and Treasure Found in Polish Lake Could Be Connected to Ancient Water Ritual.” Smithsonian. 1/26/2024. https://www.smithsonianmag.com/smart-news/ancient-europeans-buried-bodies-and-treasure-in-this-polish-lake-180983666/ Anderson, Sonja. “Just How Old Are the Cave Paintings in Spain's Cova Dones?.” Smithsonian Magazine. January/February 2024. https://www.smithsonianmag.com/history/how-old-cave-paintings-spain-cova-dones-180983456/ Anderson, Sonja. “Police Find Ancient Teenager's Body, Preserved in Irish Bog for 2,500 Years.” 2/6/2024. https://www.smithsonianmag.com/smart-news/a-bog-in-northern-ireland-preserved-this-teenagers-body-for-2500-years-180983734/ Anderson, Sonja. “Sunken British Warship That Left Crew Marooned for 66 Days Has Been Identified.” Smithsonian Magazine. 3/27/2024. https://www.smithsonianmag.com/smart-news/how-the-marooned-crew-of-this-sunken-warship-escaped-the-florida-keys-in-improvised-boats-180984028/ Anderson, Sonja. “This Medieval Sword Spent 1,000 Years at the Bottom of a Polish River.” Smithsonian. 2/6/2024. https://www.smithsonianmag.com/smart-news/this-medieval-sword-spent-1000-years-at-the-bottom-of-a-polish-river-180983684/ “Megalithic ‘Blinkerwall' Found in the Baltic Sea.” 2/14/2024. https://www.archaeology.org/news/12157-240214-baltic-sea-blinkerwall “Unbaked Neolithic Bread Identified in Turkey.” 3/6/2024. https://www.archaeology.org/news/12195-240306-turkey-unbaked-bread org. “Ship's Bell Recovered From Torpedoed WWI Destroyer.” 2/15/2024. https://www.archaeology.org/news/12161-240215-jacob-jones-bell ArtNet News. “Archaeologists Discover a Medieval Kitchen in a Polish Museum's Basement.”2/8/2024. https://news.artnet.com/art-world/royal-kitchen-poland-museum-basement-2429236 Babbs, Verity. “A Chinese Imperial Robe Found in a Cardboard Box Could Fetch $60,000 at Auction.” ArtNet. 2/29/2024. https://news.artnet.com/market/imperial-robe-dreweatts-2444018 Babbs, Verity. “A Liverpool Museum Wants Your Help to ID This Enigmatic Portrait.” ArtNet. 3/22/2024. https://news.artnet.com/art-world/liverpool-museums-black-boy-information-request-2457075 Babbs, Verity. “An Artifact Found by a Metal Detectorist in Wales Is Officially Treasure.” 3/19/2024. https://news.artnet.com/art-world/silver-thimble-treasure-2454023 Babbs, Verity. “Experts Have Identified the Tombs Where Alexander the Great's Family Are Buried.” Artnet. 2/21/2024. https://news.artnet.com/art-world/alexander-the-great-father-tomb-2437376 Babbs, Verity. “Is the Secret Ingredient to Preserving Ancient Papyrus…Wasabi?.” ArtNet. 2/29/2024. https://news.artnet.com/art-world/wasabi-ancient-egyptian-papyrus-2443171 Bangor University. “Researchers locate cargo ship SS Hartdale, torpedoed in 1915.” Phys.org. 3/13/2024. https://phys.org/news/2024-03-cargo-ship-ss-hartdale-torpedoed.html#google_vignette Bartelme, Tony. “Searching for Amelia Earhart.” Post and Courier. https://www.postandcourier.com/news/special_reports/amelia-earhart-search-tony-romeo-deep-sea-vision/article_3a42e6a8-a0e5-11ee-a942-77a1581d6b19.html Binswanger, Julia. “Engravings on 2,000-Year-Old Knife Might Be the Oldest Runes Ever Found in Denmark.” 1/25/2025. https://www.smithsonianmag.com/smart-news/archaeologists-find-denmarks-oldest-written-word-on-a-2000-year-old-knife-180983650/ Binswanger, Julia. “Metal Detectorist Finds a Rare 3,000-Year-Old Dress Fastener.” Smithsonian. 3/13/2024. https://www.smithsonianmag.com/smart-news/metal-detectorist-finds-a-potentially-life-changing-3000-year-old-gold-accessory-180983770/ Cardiff University. “Evidence of ancient medieval feasting rituals uncovered in grounds of historic property.” Phys.org. 1/4/2024. https://phys.org/news/2024-01-evidence-ancient-medieval-feasting-rituals.html Cawley, Laurence & Sam Russell. “Medieval paintings found at Christ's College, Cambridge by builders.” 1/9/2024. https://www.bbc.com/news/uk-england-cambridgeshire-67926737 CBS News. “Theft of ruby slippers from "Wizard of Oz" was reformed mobster's "one last score," court memo says.” 1/21/2024. https://www.cbsnews.com/minnesota/news/reformed-mobster-one-last-score-judy-garlands-wizard-of-oz-ruby-slippers/. Clayton, Abene. “Second man charged with stealing Dorothy's Wizard of Oz ruby slippers.” The Guardian. 3/18/2024. https://www.theguardian.com/us-news/2024/mar/18/wizard-of-oz-ruby-slippers-stolen-second-man-charged “Discovery of immense fortifications dating back 4,000 years in northwestern Arabia.” Phys.org. 1/10/2024. https://phys.org/news/2024-01-discovery-immense-fortifications-dating-years.html#google_vignette “Solving the 120-year maritime mystery of the SS Nemesis.” PhysOrg. 2/26/2024. https://phys.org/news/2024-02-year-maritime-mystery-ss-nemesis.html Deb, Sopan. “Old Newspaper Stories Offer Clues to 19th-Century Shipwreck in Lake Michigan.” New York Times. 3/28/2024. https://www.nytimes.com/2024/03/28/us/uss-milwaukee-shipwreck.html?smid=em-share Deter-Wolf A, Robitaille B, Riday D, Burlot A, Sialuk Jacobsen M. Chalcolithic Tattooing: Historical and Experimental Evaluation of the Tyrolean Iceman's Body Markings. European Journal of Archaeology. Published online 2024:1-22. doi:10.1017/eaa.2024.5 Dietrich, Oliver. “Burial mounds and a chariot grave. Archaeologists discover a Neolithic burial landscape on the Eulenberg near Magdeburg.” 3/15/2024. https://idw-online.de/en/news830373 Drury-Bradey, Paul. “Huge tsunami with 20 meter waves may have wiped out Stone Age communities in Northumberland.” Phys.org. 1/29/2024. https://phys.org/news/2024-01-huge-tsunami-meter-stone-age.html#google_vignette El-Aref, Nevine. “Spanish archaeologists unearth Ptolemaic and Roman treasures in Minya's Al Bahnasa.” Ahram Online. 1/8/2024. https://english.ahram.org.eg/News/515253.aspx Eskandari, N., De Carlo, E., Zorzi, F. et al. A Bronze Age lip-paint from southeastern Iran. Sci Rep 14, 2670 (2024). https://doi.org/10.1038/s41598-024-52490-w Georgiou, Aristos. “Prehistoric Burials Reveal Early Evidence of Body Piercing 11,000 Years Ago.” Newsweek. 3/11/2024. https://www.newsweek.com/prehistoric-burials-reveal-early-evidence-body-piercing-11000-years-ago-1877984 Green, Clare. “First prehistoric person with Turner syndrome identified from ancient DNA.” Via EurekAlert. 1/11/2024. https://www.eurekalert.org/news-releases/1030707 Hemsworth, Wade. “Researchers create method to detect cases of anemia in archaeological remains.” Via EurekAlert. 2/28/2024. https://www.eurekalert.org/news-releases/1035984 Huntington, Stewart. “New NAGPRA rules: ‘We have an obligation to change'.” Indian Country Today. 3/20/2024. https://ictnews.org/news/new-nagpra-rules-we-have-an-obligation-to-change “ICT Reports: NAGPRA crackdown sends museums reeling.” Indian Country Today. 3/22/2024. https://ictnews.org/news/ict-reports-nagpra-crackdown-sends-museums-reeling Killgrove, Kristina. “1st known tuberculosis cases in Neanderthals revealed in prehistoric bone analysis.” LiveScience. 2/2/2024. https://www.livescience.com/archaeology/1st-known-tuberculosis-cases-in-neanderthals-revealed-in-prehistoric-bone-anaylsis Kuta, Sarah. “Everyone Thought This 4,000-Year-Old Tomb Had Been Destroyed. Then, an Archaeologist Found It.” Smithsonian. 1/30/2024. https://www.smithsonianmag.com/smart-news/lost-tomb-rediscovered-ireland-180983662/ Lawson-Tancred, Jo. “A Stolen Van Gogh Painting Worth $6.5 Million Will Go Back on Display.” Artnet. 2/8/2024. https://news.artnet.com/art-world/stolen-van-gogh-on-display-2430094 Lawson-Tancred, Jo. “British Museum Will Publicly Display Some of Its Stolen Gems.” 2/2/2024. https://news.artnet.com/art-world/british-museum-gems-on-display-2427128 Lawson-Tancred, Jo. “Students Make Major Breakthrough in Use of A.I. to Decipher Ancient Scrolls.” Artnet. 2/7/2024. https://news.artnet.com/art-world/students-make-major-breakthrough-in-use-of-a-i-to-decipher-ancient-scrolls-2429506 Leonardo P. Troiano et al, A remarkable assemblage of petroglyphs and dinosaur footprints in Northeast Brazil, Scientific Reports (2024). DOI: 10.1038/s41598-024-56479-3 Lewsey, Fred. “Study reveals ‘cozy domesticity' of prehistoric stilt-house dwellers in England's ancient marshland.” University of Cambridge via EurekAlert. 3/19/2024. https://www.eurekalert.org/news-releases/1037495 Marx, Danae. “Unraveling the mysteries of the Mongolian Arc: exploring a monumental 405-kilometer wall system in Eastern Mongolia.” EurekAlert. 1/3/2024. https://www.eurekalert.org/news-releases/1030161 Matthew Steggle, John Shakespeare's "Spiritual Testament" Is Not John Shakespeare's, Shakespeare Quarterly (2024). DOI: 10.1093/sq/quae003 net. “Medieval love badge discovered in Poland.” https://www.medievalists.net/2024/02/medieval-love-badge-discovered-in-poland/ Metcalfe, Tom. “3,300-year-old tablet from mysterious Hittite Empire describes catastrophic invasion of four cities.” LiveScience. 3/11/2024. https://www.livescience.com/archaeology/3300-year-old-tablet-from-mysterious-hittite-empire-describes-catastrophic-invasion-of-four-cities Metcalfe, Tom. “Undeciphered script from Easter Island may predate European colonization.” LiveScience. 2/9/2024. https://www.livescience.com/archaeology/undeciphered-script-from-easter-island-may-predate-european-colonization Moran, Tony. “First DNA study of ancient Eastern Arabians reveals malaria adaptation – study.” EurekAlert. 2/27/2024. https://www.eurekalert.org/news-releases/1035287 Morris, Steven. “Tintern Abbey excavation suggests poor people were later buried alongside lords.” Steven Morris. The Guardian. 1/3/2024. https://www.theguardian.com/science/2024/jan/04/tintern-abbey-excavation-suggests-poor-people-were-later-buried-alongside-lords O'Laughlin Frank. “‘Rising tide lifts all boats': Century-old shipwreck unearthed on Massachusetts beach.” Boston 25 News. 3/12/2024. https://www.boston25news.com/news/local/rising-tide-lifts-all-boats-century-old-shipwreck-unearthed-massachusetts-beach/DLLJF5C3DZGKJOEUU7KTRUWUZI/ org. “Archaeologists probe mysterious Canadian shipwreck.” 2/6/2024. https://phys.org/news/2024-02-archaeologists-probe-mysterious-canadian-shipwreck.html org. “Vessel off Florida Keys identified as British warship that sank in the 18th century.” 3/10/2024. https://phys.org/news/2024-03-vessel-florida-keys-british-warship.html#google_vignette Qiblawi, Adnan. “Italians Worry the Deciphering of the Herculaneum Scrolls Could Lead to More Digs.” 2/20/2024. https://news.artnet.com/art-world/italians-fear-more-herculaneum-digs-vesuvius-2437451 Quiblawi, Adnan. “Spanish Archaeologists Make the Sweet Discovery of a 19th-Century Chocolate Factory.” ArtNet. 2/15/2024. https://news.artnet.com/art-world/barcelona-19th-century-chocolate-factory-2435176 Rascius, Brendan. “Spicy wine: New study reveals ancient Romans may have had peculiar tastes.” Phys.org. 1/24/2024. https://phys.org/news/2024-01-spicy-wine-reveals-ancient-romans.html Schrader, Adam. “Ancient Lipstick Dating Back More Than Three Millennia Is Found in Iran.” ArtNet. 2/14/2024. https://news.artnet.com/art-world/ancient-lipstick-found-in-iran-2434396 Schrader, Adam. “The Van Gogh Museum Fires Four Staff Members Over Pokémon Chaos.” ArtNet. 1/24/2024. https://news.artnet.com/art-world/van-gogh-museum-fires-workers-pokemon-2422901 Shoichet, Catherine E. “A new trove of records could help many reconnect with their Irish roots. They come from a surprising source.” CNN. 3/8/2024. https://www.cnn.com/2024/03/08/world/irish-ancestry-guinness-brewery-archives-cec/index.html Smithsonian Magazine. “Metal Detectorist Finds Rare 1,500-Year-Old Gold Ring in Denmark.” 2/26/2024. https://www.smithsonianmag.com/smart-news/metal-detectorist-discovers-a-rare-1500-year-old-gold-ring-in-denmark-180983830/ ‘ South Tyrol Museum of Archaeology. “Ötzi's tattooing technique through self-experimentation.” https://www.iceman.it/en/tattootechniqueotzi/ Sullivan, Will. “Ancient DNA From Eurasian Herders Sheds Light on the Origins of Multiple Sclerosis.” Smithsonian Magazine. 1/12/2024. https://www.smithsonianmag.com/smart-news/ancient-dna-from-eurasian-herders-sheds-light-on-the-origins-of-multiple-sclerosis-180983579/ The Francis Crick Institute. “First prehistoric person with Turner syndrome identified from ancient DNA.” 1/11/2024 https://phys.org/news/2024-01-prehistoric-person-turner-syndrome-ancient.html The History Blog. “Full gamut of Neolithic occupation, funerary practices found at site in France.” http://www.thehistoryblog.com/archives/69681 The History Blog. “Medieval love token found under Gdańsk port crane.” 2/17/2024. https://www.thehistoryblog.com/archives/69492 The History Blog. “Rare medieval belt loop found in Poland.” 3/20/2024. https://www.thehistoryblog.com/archives/69734 The History Blog. “Rare Merovingian gold ring found in Jutland.” 2/20/2024. https://www.thehistoryblog.com/archives/69517 The History Blog. “Roman silver toilet spoon found in Wales.” 1/30/2024. https://www.thehistoryblog.com/archives/69380 The History Blog. “Section of Roman 3rd century wall found in Aachen.” 3/24/2024. http://www.thehistoryblog.com/archives/69767 The History Blog. “Warring States cemetery with chariot burial found in central China.” https://www.thehistoryblog.com/archives/69748 The National Archives. “Pristine sweater in parcel posted in 1807.” 2/29/2024. https://www.nationalarchives.gov.uk/about/news/pristine-sweater-found-in-parcel-posted-in-1807/ Thijs Porck, Newly Discovered Pieces of an Old English Glossed Psalter: The Alkmaar Fragments of the N-Psalter, Anglo-Saxon England (2024). DOI: 10.1017/S0263675123000121 Thorsberg, Christian. “DNA From 2,000-Year-Old Skeletons Hints at the Origins of Syphilis.” Smithsonian Magazine. 1/29/2024. https://www.smithsonianmag.com/smart-news/dna-from-2000-year-old-skeletons-hints-at-the-origins-of-syphilis-180983657/ Tondo, Lorenzo. “Archaeologists find Pompeii fresco depicting Greek mythological siblings.” The Guardian. 3/1/2024. https://www.theguardian.com/science/2024/mar/01/pompeii-fresco-phrixus-and-helle-greek-mythological-siblings S. Department of the Interior. “Interior Department Announces Final Rule for Implementation of the Native American Graves Protection and Repatriation Act.” 12/6/2023. https://www.doi.gov/pressreleases/interior-department-announces-final-rule-implementation-native-american-graves “Anglo-Saxon cemetery discovered in Lincolnshire to appear on BBC.” https://www.viking-link.com/news/anglo-saxon-cemetery-discovered-in-lincolnshire-to-appear-on-bbc-s-digging-for-britain/ Weber, Bob. “Divers involved in Franklin expedition say the 2023 season 'highly productive'.” CBC. 1/29/2024. https://www.cbc.ca/news/canada/north/franklin-expedition-update-2024-1.7097874 Whiddington, Richard. “Archaeologists in Brazil Discover 16 New Rock Art Sites.” ArtNet. 3/14/2024. https://news.artnet.com/art-world/16-new-rock-art-sites-brazil-2452134 See omnystudio.com/listener for privacy information.

Time for all the things literally or figuratively unearthed in the first quarter of 2024. Part one includes updates, burial sites, walls, edibles and potables, and art and architecture.  Research: Abdallah, Hannah. “The first Neolithic boats in the Mediterranean.” EurekAlert. 3/20/2024. https://www.eurekalert.org/news-releases/1037843 Adam Rohrlach, Cases of trisomy 21 and trisomy 18 among historic and prehistoric individuals discovered from ancient DNA, Nature Communications (2024). DOI: 10.1038/s41467-024-45438-1. www.nature.com/articles/s41467-024-45438-1 Addley, Esther. “‘Flat-packed furniture for the next life': Roman funerary bed found in London.” The Guardian. 2/5/2024. https://www.theguardian.com/science/2024/feb/05/flat-packed-furniture-for-the-next-life-roman-funerary-bed-found-in-london Alberge, Dalya. “‘Incredibly rare' discovery reveals bedbugs came to Britain with the Romans.” The Guardian. 2/3/2024. https://www.theguardian.com/environment/2024/feb/03/incredibly-rare-discovery-reveals-bedbugs-came-to-britain-with-the-romans Anderson, Sonja. “Another Mysterious Roman Dodecahedron Has Been Unearthed in England.” Smithsonian. 1/22/2024. https://www.smithsonianmag.com/smart-news/another-of-ancient-romes-mysterious-12-sided-objects-has-been-found-in-england-180983632/ Anderson, Sonja. “Bodies and Treasure Found in Polish Lake Could Be Connected to Ancient Water Ritual.” Smithsonian. 1/26/2024. https://www.smithsonianmag.com/smart-news/ancient-europeans-buried-bodies-and-treasure-in-this-polish-lake-180983666/ Anderson, Sonja. “Just How Old Are the Cave Paintings in Spain's Cova Dones?.” Smithsonian Magazine. January/February 2024. https://www.smithsonianmag.com/history/how-old-cave-paintings-spain-cova-dones-180983456/ Anderson, Sonja. “Police Find Ancient Teenager's Body, Preserved in Irish Bog for 2,500 Years.” 2/6/2024. https://www.smithsonianmag.com/smart-news/a-bog-in-northern-ireland-preserved-this-teenagers-body-for-2500-years-180983734/ Anderson, Sonja. “Sunken British Warship That Left Crew Marooned for 66 Days Has Been Identified.” Smithsonian Magazine. 3/27/2024. https://www.smithsonianmag.com/smart-news/how-the-marooned-crew-of-this-sunken-warship-escaped-the-florida-keys-in-improvised-boats-180984028/ Anderson, Sonja. “This Medieval Sword Spent 1,000 Years at the Bottom of a Polish River.” Smithsonian. 2/6/2024. https://www.smithsonianmag.com/smart-news/this-medieval-sword-spent-1000-years-at-the-bottom-of-a-polish-river-180983684/ “Megalithic ‘Blinkerwall' Found in the Baltic Sea.” 2/14/2024. https://www.archaeology.org/news/12157-240214-baltic-sea-blinkerwall “Unbaked Neolithic Bread Identified in Turkey.” 3/6/2024. https://www.archaeology.org/news/12195-240306-turkey-unbaked-bread org. “Ship's Bell Recovered From Torpedoed WWI Destroyer.” 2/15/2024. https://www.archaeology.org/news/12161-240215-jacob-jones-bell ArtNet News. “Archaeologists Discover a Medieval Kitchen in a Polish Museum's Basement.”2/8/2024. https://news.artnet.com/art-world/royal-kitchen-poland-museum-basement-2429236 Babbs, Verity. “A Chinese Imperial Robe Found in a Cardboard Box Could Fetch $60,000 at Auction.” ArtNet. 2/29/2024. https://news.artnet.com/market/imperial-robe-dreweatts-2444018 Babbs, Verity. “A Liverpool Museum Wants Your Help to ID This Enigmatic Portrait.” ArtNet. 3/22/2024. https://news.artnet.com/art-world/liverpool-museums-black-boy-information-request-2457075 Babbs, Verity. “An Artifact Found by a Metal Detectorist in Wales Is Officially Treasure.” 3/19/2024. https://news.artnet.com/art-world/silver-thimble-treasure-2454023 Babbs, Verity. “Experts Have Identified the Tombs Where Alexander the Great's Family Are Buried.” Artnet. 2/21/2024. https://news.artnet.com/art-world/alexander-the-great-father-tomb-2437376 Babbs, Verity. “Is the Secret Ingredient to Preserving Ancient Papyrus…Wasabi?.” ArtNet. 2/29/2024. https://news.artnet.com/art-world/wasabi-ancient-egyptian-papyrus-2443171 Bangor University. “Researchers locate cargo ship SS Hartdale, torpedoed in 1915.” Phys.org. 3/13/2024. https://phys.org/news/2024-03-cargo-ship-ss-hartdale-torpedoed.html#google_vignette Bartelme, Tony. “Searching for Amelia Earhart.” Post and Courier. https://www.postandcourier.com/news/special_reports/amelia-earhart-search-tony-romeo-deep-sea-vision/article_3a42e6a8-a0e5-11ee-a942-77a1581d6b19.html Binswanger, Julia. “Engravings on 2,000-Year-Old Knife Might Be the Oldest Runes Ever Found in Denmark.” 1/25/2025. https://www.smithsonianmag.com/smart-news/archaeologists-find-denmarks-oldest-written-word-on-a-2000-year-old-knife-180983650/ Binswanger, Julia. “Metal Detectorist Finds a Rare 3,000-Year-Old Dress Fastener.” Smithsonian. 3/13/2024. https://www.smithsonianmag.com/smart-news/metal-detectorist-finds-a-potentially-life-changing-3000-year-old-gold-accessory-180983770/ Cardiff University. “Evidence of ancient medieval feasting rituals uncovered in grounds of historic property.” Phys.org. 1/4/2024. https://phys.org/news/2024-01-evidence-ancient-medieval-feasting-rituals.html Cawley, Laurence & Sam Russell. “Medieval paintings found at Christ's College, Cambridge by builders.” 1/9/2024. https://www.bbc.com/news/uk-england-cambridgeshire-67926737 CBS News. “Theft of ruby slippers from "Wizard of Oz" was reformed mobster's "one last score," court memo says.” 1/21/2024. https://www.cbsnews.com/minnesota/news/reformed-mobster-one-last-score-judy-garlands-wizard-of-oz-ruby-slippers/. Clayton, Abene. “Second man charged with stealing Dorothy's Wizard of Oz ruby slippers.” The Guardian. 3/18/2024. https://www.theguardian.com/us-news/2024/mar/18/wizard-of-oz-ruby-slippers-stolen-second-man-charged “Discovery of immense fortifications dating back 4,000 years in northwestern Arabia.” Phys.org. 1/10/2024. https://phys.org/news/2024-01-discovery-immense-fortifications-dating-years.html#google_vignette “Solving the 120-year maritime mystery of the SS Nemesis.” PhysOrg. 2/26/2024. https://phys.org/news/2024-02-year-maritime-mystery-ss-nemesis.html Deb, Sopan. “Old Newspaper Stories Offer Clues to 19th-Century Shipwreck in Lake Michigan.” New York Times. 3/28/2024. https://www.nytimes.com/2024/03/28/us/uss-milwaukee-shipwreck.html?smid=em-share Deter-Wolf A, Robitaille B, Riday D, Burlot A, Sialuk Jacobsen M. Chalcolithic Tattooing: Historical and Experimental Evaluation of the Tyrolean Iceman's Body Markings. European Journal of Archaeology. Published online 2024:1-22. doi:10.1017/eaa.2024.5 Dietrich, Oliver. “Burial mounds and a chariot grave. Archaeologists discover a Neolithic burial landscape on the Eulenberg near Magdeburg.” 3/15/2024. https://idw-online.de/en/news830373 Drury-Bradey, Paul. “Huge tsunami with 20 meter waves may have wiped out Stone Age communities in Northumberland.” Phys.org. 1/29/2024. https://phys.org/news/2024-01-huge-tsunami-meter-stone-age.html#google_vignette El-Aref, Nevine. “Spanish archaeologists unearth Ptolemaic and Roman treasures in Minya's Al Bahnasa.” Ahram Online. 1/8/2024. https://english.ahram.org.eg/News/515253.aspx Eskandari, N., De Carlo, E., Zorzi, F. et al. A Bronze Age lip-paint from southeastern Iran. Sci Rep 14, 2670 (2024). https://doi.org/10.1038/s41598-024-52490-w Georgiou, Aristos. “Prehistoric Burials Reveal Early Evidence of Body Piercing 11,000 Years Ago.” Newsweek. 3/11/2024. https://www.newsweek.com/prehistoric-burials-reveal-early-evidence-body-piercing-11000-years-ago-1877984 Green, Clare. “First prehistoric person with Turner syndrome identified from ancient DNA.” Via EurekAlert. 1/11/2024. https://www.eurekalert.org/news-releases/1030707 Hemsworth, Wade. “Researchers create method to detect cases of anemia in archaeological remains.” Via EurekAlert. 2/28/2024. https://www.eurekalert.org/news-releases/1035984 Huntington, Stewart. “New NAGPRA rules: ‘We have an obligation to change'.” Indian Country Today. 3/20/2024. https://ictnews.org/news/new-nagpra-rules-we-have-an-obligation-to-change “ICT Reports: NAGPRA crackdown sends museums reeling.” Indian Country Today. 3/22/2024. https://ictnews.org/news/ict-reports-nagpra-crackdown-sends-museums-reeling Killgrove, Kristina. “1st known tuberculosis cases in Neanderthals revealed in prehistoric bone analysis.” LiveScience. 2/2/2024. https://www.livescience.com/archaeology/1st-known-tuberculosis-cases-in-neanderthals-revealed-in-prehistoric-bone-anaylsis Kuta, Sarah. “Everyone Thought This 4,000-Year-Old Tomb Had Been Destroyed. Then, an Archaeologist Found It.” Smithsonian. 1/30/2024. https://www.smithsonianmag.com/smart-news/lost-tomb-rediscovered-ireland-180983662/ Lawson-Tancred, Jo. “A Stolen Van Gogh Painting Worth $6.5 Million Will Go Back on Display.” Artnet. 2/8/2024. https://news.artnet.com/art-world/stolen-van-gogh-on-display-2430094 Lawson-Tancred, Jo. “British Museum Will Publicly Display Some of Its Stolen Gems.” 2/2/2024. https://news.artnet.com/art-world/british-museum-gems-on-display-2427128 Lawson-Tancred, Jo. “Students Make Major Breakthrough in Use of A.I. to Decipher Ancient Scrolls.” Artnet. 2/7/2024. https://news.artnet.com/art-world/students-make-major-breakthrough-in-use-of-a-i-to-decipher-ancient-scrolls-2429506 Leonardo P. Troiano et al, A remarkable assemblage of petroglyphs and dinosaur footprints in Northeast Brazil, Scientific Reports (2024). DOI: 10.1038/s41598-024-56479-3 Lewsey, Fred. “Study reveals ‘cozy domesticity' of prehistoric stilt-house dwellers in England's ancient marshland.” University of Cambridge via EurekAlert. 3/19/2024. https://www.eurekalert.org/news-releases/1037495 Marx, Danae. “Unraveling the mysteries of the Mongolian Arc: exploring a monumental 405-kilometer wall system in Eastern Mongolia.” EurekAlert. 1/3/2024. https://www.eurekalert.org/news-releases/1030161 Matthew Steggle, John Shakespeare's "Spiritual Testament" Is Not John Shakespeare's, Shakespeare Quarterly (2024). DOI: 10.1093/sq/quae003 net. “Medieval love badge discovered in Poland.” https://www.medievalists.net/2024/02/medieval-love-badge-discovered-in-poland/ Metcalfe, Tom. “3,300-year-old tablet from mysterious Hittite Empire describes catastrophic invasion of four cities.” LiveScience. 3/11/2024. https://www.livescience.com/archaeology/3300-year-old-tablet-from-mysterious-hittite-empire-describes-catastrophic-invasion-of-four-cities Metcalfe, Tom. “Undeciphered script from Easter Island may predate European colonization.” LiveScience. 2/9/2024. https://www.livescience.com/archaeology/undeciphered-script-from-easter-island-may-predate-european-colonization Moran, Tony. “First DNA study of ancient Eastern Arabians reveals malaria adaptation – study.” EurekAlert. 2/27/2024. https://www.eurekalert.org/news-releases/1035287 Morris, Steven. “Tintern Abbey excavation suggests poor people were later buried alongside lords.” Steven Morris. The Guardian. 1/3/2024. https://www.theguardian.com/science/2024/jan/04/tintern-abbey-excavation-suggests-poor-people-were-later-buried-alongside-lords O'Laughlin Frank. “‘Rising tide lifts all boats': Century-old shipwreck unearthed on Massachusetts beach.” Boston 25 News. 3/12/2024. https://www.boston25news.com/news/local/rising-tide-lifts-all-boats-century-old-shipwreck-unearthed-massachusetts-beach/DLLJF5C3DZGKJOEUU7KTRUWUZI/ org. “Archaeologists probe mysterious Canadian shipwreck.” 2/6/2024. https://phys.org/news/2024-02-archaeologists-probe-mysterious-canadian-shipwreck.html org. “Vessel off Florida Keys identified as British warship that sank in the 18th century.” 3/10/2024. https://phys.org/news/2024-03-vessel-florida-keys-british-warship.html#google_vignette Qiblawi, Adnan. “Italians Worry the Deciphering of the Herculaneum Scrolls Could Lead to More Digs.” 2/20/2024. https://news.artnet.com/art-world/italians-fear-more-herculaneum-digs-vesuvius-2437451 Quiblawi, Adnan. “Spanish Archaeologists Make the Sweet Discovery of a 19th-Century Chocolate Factory.” ArtNet. 2/15/2024. https://news.artnet.com/art-world/barcelona-19th-century-chocolate-factory-2435176 Rascius, Brendan. “Spicy wine: New study reveals ancient Romans may have had peculiar tastes.” Phys.org. 1/24/2024. https://phys.org/news/2024-01-spicy-wine-reveals-ancient-romans.html Schrader, Adam. “Ancient Lipstick Dating Back More Than Three Millennia Is Found in Iran.” ArtNet. 2/14/2024. https://news.artnet.com/art-world/ancient-lipstick-found-in-iran-2434396 Schrader, Adam. “The Van Gogh Museum Fires Four Staff Members Over Pokémon Chaos.” ArtNet. 1/24/2024. https://news.artnet.com/art-world/van-gogh-museum-fires-workers-pokemon-2422901 Shoichet, Catherine E. “A new trove of records could help many reconnect with their Irish roots. They come from a surprising source.” CNN. 3/8/2024. https://www.cnn.com/2024/03/08/world/irish-ancestry-guinness-brewery-archives-cec/index.html Smithsonian Magazine. “Metal Detectorist Finds Rare 1,500-Year-Old Gold Ring in Denmark.” 2/26/2024. https://www.smithsonianmag.com/smart-news/metal-detectorist-discovers-a-rare-1500-year-old-gold-ring-in-denmark-180983830/ ‘ South Tyrol Museum of Archaeology. “Ötzi's tattooing technique through self-experimentation.” https://www.iceman.it/en/tattootechniqueotzi/ Sullivan, Will. “Ancient DNA From Eurasian Herders Sheds Light on the Origins of Multiple Sclerosis.” Smithsonian Magazine. 1/12/2024. https://www.smithsonianmag.com/smart-news/ancient-dna-from-eurasian-herders-sheds-light-on-the-origins-of-multiple-sclerosis-180983579/ The Francis Crick Institute. “First prehistoric person with Turner syndrome identified from ancient DNA.” 1/11/2024 https://phys.org/news/2024-01-prehistoric-person-turner-syndrome-ancient.html The History Blog. “Full gamut of Neolithic occupation, funerary practices found at site in France.” http://www.thehistoryblog.com/archives/69681 The History Blog. “Medieval love token found under Gdańsk port crane.” 2/17/2024. https://www.thehistoryblog.com/archives/69492 The History Blog. “Rare medieval belt loop found in Poland.” 3/20/2024. https://www.thehistoryblog.com/archives/69734 The History Blog. “Rare Merovingian gold ring found in Jutland.” 2/20/2024. https://www.thehistoryblog.com/archives/69517 The History Blog. “Roman silver toilet spoon found in Wales.” 1/30/2024. https://www.thehistoryblog.com/archives/69380 The History Blog. “Section of Roman 3rd century wall found in Aachen.” 3/24/2024. http://www.thehistoryblog.com/archives/69767 The History Blog. “Warring States cemetery with chariot burial found in central China.” https://www.thehistoryblog.com/archives/69748 The National Archives. “Pristine sweater in parcel posted in 1807.” 2/29/2024. https://www.nationalarchives.gov.uk/about/news/pristine-sweater-found-in-parcel-posted-in-1807/ Thijs Porck, Newly Discovered Pieces of an Old English Glossed Psalter: The Alkmaar Fragments of the N-Psalter, Anglo-Saxon England (2024). DOI: 10.1017/S0263675123000121 Thorsberg, Christian. “DNA From 2,000-Year-Old Skeletons Hints at the Origins of Syphilis.” Smithsonian Magazine. 1/29/2024. https://www.smithsonianmag.com/smart-news/dna-from-2000-year-old-skeletons-hints-at-the-origins-of-syphilis-180983657/ Tondo, Lorenzo. “Archaeologists find Pompeii fresco depicting Greek mythological siblings.” The Guardian. 3/1/2024. https://www.theguardian.com/science/2024/mar/01/pompeii-fresco-phrixus-and-helle-greek-mythological-siblings S. Department of the Interior. “Interior Department Announces Final Rule for Implementation of the Native American Graves Protection and Repatriation Act.” 12/6/2023. https://www.doi.gov/pressreleases/interior-department-announces-final-rule-implementation-native-american-graves “Anglo-Saxon cemetery discovered in Lincolnshire to appear on BBC.” https://www.viking-link.com/news/anglo-saxon-cemetery-discovered-in-lincolnshire-to-appear-on-bbc-s-digging-for-britain/ Weber, Bob. “Divers involved in Franklin expedition say the 2023 season 'highly productive'.” CBC. 1/29/2024. https://www.cbc.ca/news/canada/north/franklin-expedition-update-2024-1.7097874 Whiddington, Richard. “Archaeologists in Brazil Discover 16 New Rock Art Sites.” ArtNet. 3/14/2024. https://news.artnet.com/art-world/16-new-rock-art-sites-brazil-2452134 See omnystudio.com/listener for privacy information.

We look into the engineering reasons why the Francis Scott Key bridge collapsed after a ship crashed into it. Also, a new analysis finds that more viruses spread from humans to animals than from animals to humans.The Engineering Behind Why The Bridge In Baltimore CollapsedOn Tuesday, a large section of Baltimore's Francis Scott Key bridge collapsed after an enormous container ship lost power and collided with the structure. Two people were rescued from the water, two bodies were recovered, and four others are unaccounted for and presumed dead.The structural failure of the bridge, which cut off a key roadway and a major international shipping port, has many wondering why this happened. Does the fault lie in aging infrastructure or in the manner the container ship struck one of the bridge's main supports?Guest host Arielle Duhaime-Ross talks to journalist Swapna Krishna about the engineering reasons behind why the bridge collapsed and other top stories in science this week, including rockets NASA is launching during next week's solar eclipse, new research about how Homo sapiens traveled out of Africa, and visualizing the magnetic field of the black hole at the center of our galaxy.Mapping Out How Viruses Jump Between SpeciesIn the world of emerging infectious diseases, one of the looming threats comes from the so-called zoonotic diseases—pathogens that somehow make the jump from an animal host to a human one. This includes pathogens such as COVID-19 and avian influenza, a.k.a. bird flu, which can sometimes cross the species divide. But a new analysis published in the journal Nature Ecology and Evolution finds that when it comes to viruses, more viral species appear to have jumped from humans to animals than the other way around. And even more cases of interspecies transmission don't involve humans at all.Cedric Tan, a PhD student in the University College London Genetics Institute and Francis Crick Institute, joins guest host Arielle Duhaime-Ross to talk about the analysis, and what it tells us about our place in a global web of viruses.Transcripts for each segment will be available after the show airs on sciencefriday.com.  Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Angela is joined by special guest, Dr. Andrew Steele to discuss the topic of aging and longevity. Dr. Steele shares insights on the biology of aging, potential advancements in anti-aging treatments, and the importance of funding aging biology research. They also delve into various aspects of aging, including the ten hallmarks of aging, the role of mitochondria, and the impact of telomere length. Dr. Steele touches on the differences in aging between men and women, highlighting the unique evolutionary aspects of menopause and mitochondrial inheritance KEY TAKEAWAYS Dr. Steele discusses the importance of evidence-based research when it comes to supplements and aging. Should aging be seen as a disease of some kind, with considerations for regulatory advantages and perspective shifts? The 10 hallmarks of aging include DNA damage, telomere shortening, protein dysfunction, mitochondrial issues, and immune system changes. Mitochondria, known as the powerhouse of the cell, play a crucial role in energy production and aging processes. Evolutionary theories, such as the grandmother hypothesis, shed light on menopause and longevity differences between genders. BEST MOMENTS "The best piece of health advice is to campaign for more funding for aging biology research." "We've got ideas for how to slow down the aging process, how maybe even to reverse it." "The risk of death doubles about every eight years. This is a phenomenally universal fact of being human." "Mitochondria are the only part of your cell that have their own DNA." VALUABLE RESOURCES Get a free snapshot of your health and personalised report at www.yourtotalhealthcheck.com Join The High Performance Health CommunityFree Fasting Guide - www.angelafosterperformance.com/fastingPodcast Shownotes - www.angelafosterperformance.com/podcasts AG1 Special Offer - https://www.drinkag1.com/angelafoster  Get £30 off a Veri Continuous Glucose Monitor (CGM) - https://angelafoster.me/cgm ABOUT THE GUEST DR ANDREW STEELE I am a scientist, writer and campaigner based in Berlin, and author of Ageless: The new science of getting older without getting old. After a PhD in physics from the University of Oxford, I decided that ageing was the single most important scientific challenge of our time, and switched fields to computational biology. I worked at the Francis Crick Institute, using machine learning to decode our DNA and predict heart attacks using patients' NHS medical records. I'm now a full-time science writer and presenter. I've written for the Wall Street Journal, Sunday Times, Telegraph, Guardian and WIRED magazine, and have featured on NBC's TODAY, The Russell Howard Hour, Sunday Brunch, NBC Morning News Now and BBC News, as well as being a regular expert on Discovery's Impossible Engineering and Strangest Things on Sky. I also produce videos on my YouTube channel, and give live talks ranging from lectures in schools to science stand-up (yes, that is a thing) at the Hammersmith Apollo. I've also campaigned about science funding as Chair of Science is Vital and creator of Scienceogram. Contact: https://www.youtube.com/DrAndrewSteele https://www.instagram.com/andrewjsteele https://twitter.com/statto https://www.facebook.com/DrAndrewSteele https://steele.link/  ABOUT THE HOST Angela Foster is an award winning Nutritionist, Health & Performance Coach, Speaker and Host of the High Performance Health podcast. A former Corporate lawyer turned industry leader in biohacking and health optimisation for women, Angela has been featured in various media including Huff Post, Runners world, The Health Optimisation Summit, BrainTap, The Women's Biohacking Conference, Livestrong & Natural Health Magazine. Angela is the creator of BioSyncing®️ a blueprint for ambitious entrepreneurial women to biohack their health so they can 10X how they show up in their business and their family without burning out. Angela's BioSyncing®️ Blueprint is currently closed. Click here to get on the waitlist. The High Performance Health Podcast is a top rated global podcast. Each week, Angela brings you a new insight, biohack or high performance habit to help you unlock optimal health, longevity and higher performance. Hit the follow button to make sure you get notified each time Angela releases a new episode. CONTACT DETAILS Instagram Facebook LinkedIn

Adam visits the Hello Brain exhibition at the Francis Crick Institute in London, a free showcase focusing on the brain and its complexities! The exhibition, curated by Holly Cave, highlights the brain's 86 billion neurones and their interactions, using both scientific displays and community-created art to illustrate concepts. The Francis Crick Institute, a major scientific research facility, hosts this exhibition, offering a unique blend of current research and historical context in neuroscience.Join Fun Kids Podcasts+: https://funkidslive.com/plusSee omnystudio.com/listener for privacy information.

Sir Paul Nurse, Director of the Francis Crick Institute in London, UK is a Nobel Prize winning geneticist and cell biologist whose research is recognised worldwide, particularly for his contributions to cell biology and cancer research. In this insightful interview with our sister publication, Research Features, Nurse discusses the institute's creative ‘bottom up' approach to research, his presidency of the Royal Society, science communication, and how he stays grounded despite a staggeringly successful career.Read more in Research Features: doi.org/10.26904/RF-150-5477109273Visit the Francis Crick Institute's website: crick.ac.uk

Brain implants have been sparking conversation about the future of humanity after Elon Musk's company Neuralink announced it has embedded a microship in a human skull. It's fired up people's imaginations and led some to wonder whether these devices that connect to our brain could be a stepping stone towards the ideas more often found in sci-fi, and maybe even create a tool to read people's thoughts. Marnie and the panel discuss whether our privacy is at risk or whether we're already an open book; they try to understand the concept of backing up our brains, and they meet Dr Michael Winding from the Francis Crick Institute in the UK to hear about a pioneering and painstaking study which involved years and years of work to map the pathways of a brain, and you might be surprised how small that brain was.Plus, Katie Tomsett looks at how tattoos could be used to indicate the health of our bodies; in Under the Radar we learn how batteries could one day charge through sound, we hear the story of an alleged spy pigeon caught in India, and we highlight the wonderful tale of a beluga whale.Presenter: Marnie Chesterton, with Chhavi Sachdev and Kai Kupferschmidt Producer: Tom Bonnett, with Alex Mansfield, Dan Welsh, Katie Tomsett and Jack Lee

The psychologist, writer and journalist Daniel Goleman is the author the bestselling book Emotional Intelligence and many more popular titles exploring the workings of the mind. His new book, co-authored with fellow psychologist and academic Cary Cherniss, is Optimal: How to Sustain Excellence Every Day. The book highlights practical methods for applying the principles of emotional intelligence to everyday life so more people can enter an optimal state of high performance – offering a roadmap to how to be your best, every day. Joining Goleman to discuss the book is molecular biologist and science communicator Dr Güneş Taylor, postdoctoral research scientist at The Francis Crick Institute. If you'd like to get access to all of our longer form interviews and members-only content, just visit intelligencesquared.com/membership to find out more. For £4.99 per month you'll also receive: - Full-length and ad-free Intelligence Squared episodes, wherever you get your podcasts - Bonus Intelligence Squared podcasts, curated feeds and members exclusive series - 15% discount on livestreams and in-person tickets for all Intelligence Squared events - Our member-only newsletter The Monthly Read, sent straight to your inbox ... Or Subscribe on Apple for £4.99: - Full-length and ad-free Intelligence Squared podcasts - Bonus Intelligence Squared podcasts, curated feeds and members exclusive series ... Already a subscriber? Thank you for supporting our mission to foster honest debate and compelling conversations! Visit intelligencesquared.com to explore all your benefits including ad-free podcasts, exclusive bonus content, early access and much more ... Subscribe to our newsletter here to hear about our latest events, discounts and much more. https://www.intelligencesquared.com/newsletter-signup/ Learn more about your ad choices. Visit podcastchoices.com/adchoices

Climate change is threatening human health across the globe. Extreme weather events like wildfires and heat waves are causing immediate and long-term health risks, with sometimes deadly results. According to this year's Lancet Countdown report, which tracks the effects of climate change on human health, the impacts are getting worse.  To address this growing crisis, the recent UN Conference on Climate Change, or COP28, featured its first ever Health Day. Discussions there established the issue as a vital factor in climate negotiations. But the final agreement from the climate talks does not include the phasing out of fossil fuels, which is language many health experts were hoping to see included.  So, how do researchers track the connection between climate change and human health? What are the key indicators? And what do they warn will be the consequences of continuing to burn fossil fuels?  This week host Bill Loveless talks with Dr. Marina Romanello about the intersection of health and climate change.  Marina is the executive director of the Lancet Countdown, and a climate change and health researcher at University College London. She has also carried out research in the Buenos Aires Institute of Technology, University of Cambridge, and the Francis Crick Institute. From 2020-2021, Marina helped England's National Health System develop net-zero commitments.

In this episode of Mommy Brain Revisited I talk with Dr Jonny Kohl, Group Leader, State-Dependent Neural Processing Laboratory, The Francis Crick Institute, London, UK. We talk about his new research on how the hormones of pregnancy affect specific neurons in the MPOA that essential for parenting. It's a fascinating new finding and provides valuable insight into the neuroendocrine factors governing parental care. We also talk about whether or not we should be using reproductively experienced females more in general neuroscience research because of the long-term impact of pregnancy on the brain, the importance of state in general and practical considerations for doing these types of studies. It's a good one. You won't want to miss it. For more information on Dr Kohl and his group: https://www.crick.ac.uk/research/find-a-researcher/jonny-kohl Here is a link to the paper we talk about: https://www.science.org/doi/10.1126/science.adi0576 --- Support this podcast: https://podcasters.spotify.com/pod/show/mommybrainrevisited/support

In this episode of Microbe Talk, our Policy and Engagement Officer Katie chats to Sir Paul Nurse, Director of the Francis Crick Institute and former President of the Royal Society. He was awarded the 2001 Nobel Prize in Physiology or Medicine for his discovery of protein molecules that control the division of cells in the cell cycle and has since received over 70 honorary degrees. In this episode, Katie and Paul talk about the importance of collaboration and co-working in science, and discuss the UK's recent re-association with Horizon Europe, the EU funding programme for research and innovation.A full transcript of this episode is available on the Microbiology Society website.You can read the official Microbiology Society response to the UK's re-association with Horizon Europe, here.Music: Glossy by Yrii Semchyshyn from Pixabay

Philip Gold is one of the world's leading researchers of depressive illness. Since 1974, he has worked at the National Institute of Health, where he has served as Chief of Neuroendocrine Research, and Senior Investigator in the National Institute of Mental Health Intramural Research Program, and Chief of the Section on Neuroendocrinology. For this episode, he joins science communicator and Postdoctoral fellow at The Francis Crick Institute, Dr Güneş Taylor, in conversation to talk about his life's work and the findings of his recent book: Breaking Through Depression.  We'd love to hear your feedback and what you think we should talk about next, who we should have on and what our future debates should be.  Send us an email or voice note with your thoughts to podcasts@intelligencesquared.com or Tweet us @intelligence2. And if you'd like to support our mission to foster honest debate and compelling conversations, as well as ad-free podcasts, exclusive bonus content, early access and much more, become a supporter of Intelligence Squared. Just visit intelligencesquared.com/membership to find out more.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Award-winning journalist Oliver Franklin-Wallis has spent the last number of years investigating the global waste industry. In June 2023 he came to Intelligence Squared to tell us the truth about Britain's overflowing sewers and hollowed-out mining towns, the mountainous landfills of New Delhi, Ghana's flooded second-hand markets and what it all means for the future. Joining him to discuss the book is Dr Güneş Taylor, science communicator and Postdoctoral fellow at The Francis Crick Institute. We'd love to hear your feedback and what you think we should talk about next, who we should have on and what our future debates should be.  Send us an email or voice note with your thoughts to podcasts@intelligencesquared.com or Tweet us @intelligence2.  And if you'd like to support our mission to foster honest debate and compelling conversations, as well as ad-free podcasts, exclusive bonus content, early access and much more, become a supporter of Intelligence Squared. Just visit intelligencesquared.com/membership to find out more.  Learn more about your ad choices. Visit megaphone.fm/adchoices

This month, we're delighted to speak to Prof Gerard Evan who is based at the UK's Francis Crick Institute and is one of the world's leading cancer researchers. Prof Evan talks to Tatum about why cancers occur, how we can treat them, and why there are many reasons to be hopeful for the future of cancer treatment. Fun fact: you have more cells in your body than there are stars in a thousand Milky Way galaxies. Like what you hear? Join us *in person* on 14 October at Shine Connect, the UK's only conference for younger adults with cancer. Find out all the details and register here. 

#62 — Lucy Collinson (The Francis Crick Institute) and Kirk Czymmek (The Donald Danforth Plant Science Center) join Peter O'Toole to discuss volume EM. Together they highlight what volume EM is, how it has been a quiet revolution, and share resources to help those wanting to get started using this powerful new technology. They discuss how amazingly friendly and engaged the volume EM community is, how you can get involved, and the dangers of saying web addresses too quickly. Watch or listen to all episodes of The Microscopists: themicroscopists.bitesizebio.com

After obtaining a PhD in physics from the University of Oxford, Andrew Steele decided that aging was the most important scientific challenge of our time and switched fields to computational biology. He worked at the Francis Crick Institute, using machine learning to decode our DNA and predict heart attacks using patients' medical records. He is now a full-time science writer and presenter based in London. Andrew is the author of the book "Ageless: The New Science of Getting Older Without Getting Old" and you can find more from Andrew at: https://andrewsteele.co.uk/ Connect with us: https://freedompact.co.uk/newsletter​ (Healthy, Wealthy & Wise Newsletter) https://instagram.com/freedompact​ https://twitter.com/freedompactpod freedompact@gmail.com

Expert responds to big tech's AI extinction warning. Researchers find 4,000-year-old plague DNA in Britain. North Korea's failed attempt to launch first spy satellite into space. Why we need to tackle in-flight cabin fumes. In this episode:Cecilia Rikap from City, University of London on artificial intelligence ‘extinction' warningPontus Skoglund and Pooja Swali from the Francis Crick Institute explain 4,000-year-old plague DNA discoveryChinese Scientist: 'Don't rule out' COVID-19 lab leak theory‘Smart bandages' could improve outcomes for patients with non-healing woundsWhy fish are relocating to colder watersThe Red panda that escaped from Newquay ZooFollow us on Twitter #TechScienceDaily Hosted on Acast. See acast.com/privacy for more information.

Researchers from London's Francis Crick Institute have found a type of artificial sweetener is able to dampen down immune system responses - at least in mice. Karen Vousden and Fabio Zani tell us about the implications. And Ronan McCarthy from Brunel University has found a range of different artificial sweeteners have antibacterial properties. We discuss the connections between these two areas of research and the prospect of developing drug treatments from artificial sweeteners. Penny Johnes from Bristol University discusses the use of phosphorus in agriculture, it's a key component of fertilisers, but global supplies may run out in a few years, despite this overuse of phosphorus in agriculture is also creating problems. And Chat GPT has had a makeover, a new version of the chatbot was rolled out this week. Chatbots seem to be getting a lot of press at the moment, but are they really something we will all be using in the future? Technologist and composer LJ Rich who works with the UN on artificial intelligence gives us her analysis. BBC Inside Science is produced in collaboration with the Open University.

The government has launched a new 10-point plan designed, it said to “cement the UK's place as a global science and technology superpower”. We speak with Sir Paul Nurse, director of the Francis Crick Institute, for his take on the government's plan and the findings of his own review of the UK's research landscape. In 1963, in a now famous speech at the Labour Party conference in Scarborough, Labour leader and soon to be Prime Minister Harold Wilson promised a new Britain would be forged in the “white heat" of a "scientific revolution". Nick Thomas Symonds, Labour MP and political biographer, discusses how that idea was put into action. Scientists in Bristol have published a detailed "future flood map" of Britain - simulating the impacts of flooding as climate change takes its toll. Paul Bates from Bristol University explains how the new flood risk maps give a level of detail that could help people to plan and adapt. Vic Gill visits the Calder Valley in West Yorkshire, a place that's suffered repeated flooding in recent years, where the community is taking matters into its own hands. New fossil findings from China have led scientists to re-evaluate their classification of tiny tentacled sea creatures from half a billion years ago and declare that they are in fact seaweeds says Martin Smith, a paleobiologist from The University of Durham. And this re-classification isn't unusual, fossils are constantly re-examined in light of new evidence and insights. Susie Maidment a paleobiologist at the Natural History Museum takes us through some of her favourite contentious fossils. Presenter: Victoria Gill Producers: Julian Siddle and Emily Bird BBC Inside Science is produced in collaboration with the Open University

Ever since the discovery of DNA scientists have been on a quest to understand the secrets of the human genome. This quest has not only involved analysing the role genes play in making us who we are – the history of genetics has also been shaped by a desire to explore how far our genes can be altered or enhanced.  In 2012, the discovery that a molecule known as CRISPR could be programmed to add and remove elements of DNA marked a huge leap forward, transforming research into treatments for diseases as varied as cancer, Alzheimer's, sickle cell and HIV, as well as many rare genetic conditions.  In this conversation, recorded at the Francis Crick Institute in London, our panel explores the urgent ethical questions that these advances have unleashed. Chaired by Dr Guddi Singh, the panel featured Tom Whipple, Science Editor at The Times, Shani Dhanda, an award-winning disability activist and inclusion specialist, Dr Güneş Taylor, postdoctoral research scientist at the Francis Crick Institute, and Jimi Olaghere, one of the first people in the world to take part in a life-changing clinical trial using gene therapy to treat sickle cell disease.  In this episode (Part II) the panel responds to questions from the audience on the real life implications of gene editing, and the role society should play in regulating the field. If you missed part one of this conversation, please go back and listen now. The event was organised to coincide with a free exhibition at the Francis Crick Institute, London called ‘Cut and Paste,' exploring the future and ethics of gene editing. The exhibition runs until December 2023. Visit https://www.crick.ac.uk/CutandPaste to find out more.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Ever since the discovery of DNA scientists have been on a quest to understand the secrets of the human genome. This quest has not only involved analysing the role genes play in making us who we are – the history of genetics has also been shaped by a desire to explore how far our genes can be altered or enhanced.  In 2012, the discovery that a tool known as CRISPR could be programmed to add and remove elements of DNA marked a huge leap forward, transforming research into treatments for diseases as varied as cancer, Alzheimer's, sickle cell and HIV, as well as many rare genetic conditions.  In this conversation, recorded at the Francis Crick Institute in London, our panel explores the urgent ethical questions that these advances have unleashed. Chaired by Dr Guddi Singh, the panel featured Tom Whipple, Science Editor at The Times, Shani Dhanda, an award-winning disability activist and inclusion specialist, Dr Güneş Taylor, postdoctoral research scientist at the Francis Crick Institute, and Jimi Olaghere, one of the first people in the world to take part in a life-changing clinical trial using gene therapy to treat sickle cell disease.  In this episode (Part I) the panel explores questions such as: what diseases should we try to cure? How should these be prioritised? What assumptions shape perceptions of disability? Where does the line between editing and enhancing fall? And ultimately who gets to decide?  The event was organised to coincide with a free exhibition at the Francis Crick Institute, London called ‘Cut + Paste,' exploring the future and ethics of gene editing. The exhibition runs until December 2023. Visit www.crick.ac.uk/CutandPaste to find out more.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Ian Sample speaks to Guardian science correspondent Hannah Devlin about the latest developments and debates about gene editing to emerge from a summit at the Francis Crick Institute in London. The summit heard from the first person with sickle cell disease to be treated with a technique known as Crispr. He also hears from Prof Claire Booth about ensuring these cutting edge treatments are made available to everyone who needs them. Help support our independent journalism at theguardian.com/sciencepod

The Third International Summit on Human Genome Editing was held this week in London. It was the first such meeting since 2018, when a Chinese researcher announced that he had created the world's first genetically edited babies—a move that was roundly condemned at the time. Host Alok Jha and Natasha Loder, The Economist's health editor, report from the conference to explore the exciting future—and knotty challenges—of the world that gene-editing therapies could create.Robin Lovell-Badge, a leading scientist at the Francis Crick Institute in London and the organiser of the summit, explains how genome-editing technology has rapidly advanced in recent years. Claire Booth, a professor of gene therapy and paediatric immunology at Great Ormond Street Hospital and University College London discusses the hopes of gene-editing treatments. Plus, Kelly Ormond, a bioethicist from ETH-Zurich, explores the ethical dilemmas that are raised by the technology, and Filippa Lentzos of King's College London, explains why human genome editing presents potential biosecurity risks.Listen to previous episodes of “Babbage” on the topic: the gene therapy revolution and an interview with Jennifer Doudna, the pioneer of CRISPR-Cas9 technology. For full access to The Economist's print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience. Hosted on Acast. See acast.com/privacy for more information.

The Third International Summit on Human Genome Editing was held this week in London. It was the first such meeting since 2018, when a Chinese researcher announced that he had created the world's first genetically edited babies—a move that was roundly condemned at the time. Host Alok Jha and Natasha Loder, The Economist's health editor, report from the conference to explore the exciting future—and knotty challenges—of the world that gene-editing therapies could create.Robin Lovell-Badge, a leading scientist at the Francis Crick Institute in London and the organiser of the summit, explains how genome-editing technology has rapidly advanced in recent years. Claire Booth, a professor of gene therapy and paediatric immunology at Great Ormond Street Hospital and University College London discusses the hopes of gene-editing treatments. Plus, Kelly Ormond, a bioethicist from ETH-Zurich, explores the ethical dilemmas that are raised by the technology, and Filippa Lentzos of King's College London, explains why human genome editing presents potential biosecurity risks.Listen to previous episodes of “Babbage” on the topic: the gene therapy revolution and an interview with Jennifer Doudna, the pioneer of CRISPR-Cas9 technology. For full access to The Economist's print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience. Hosted on Acast. See acast.com/privacy for more information.

Oops, a Study Says the New COVID Pill Is Actually Mutating the Virus Instead of stopping COVID-19, Merck's Lagevrio drug may actually help mutate the virus, according to a new, non-peer reviewed study. Merck, meanwhile, denies the accuracy of the study. Researchers from the U.S. and the U.K., including the Francis Crick Institute and Imperial College London say that the drug's purpose of mutating the COVID genome to restrict the virus from spreading within a patient may create more mutations of the virus that can then pass to other people. This is just my opinion. PS: If you enjoy my content, I will think of you while drinking my coffee. – Buy Me a Coffee The Slippery Slope Spotify J Fallon Apple Music J Fallon Spotify J Fallon YouTube The Slippery Slope Apple Podcasts The Slippery Slope YouTube The Slippery Slope Stitcher --- Send in a voice message: https://podcasters.spotify.com/pod/show/jason-fallon/message

Our guest in this episode is a Briton who is based in Berlin, namely Andrew Steele. Earlier in his life Andrew spent nine years at the University of Oxford where, among other accomplishments, he gained a PhD in physics. His focus switched to computational biology, and he held positions at Cancer Research UK and the Francis Crick Institute.Along the way, Andrew decided that aging was the single most important scientific challenge of our time. This led him to write the book "Ageless: The New Science of Getting Older Without Getting Old". There are a lot of books these days about the science of slowing, stopping, and even reversing aging, but Andrew's book is perhaps the best general scientific introduction to this whole field.Selected follow-ups:https://andrewsteele.co.uk/https://www.youtube.com/DrAndrewSteelehttps://ageless.link/Topics in this conversation include:*) The background that led Andrew to write his book "Ageless"*) A graph that changed a career*) The chance of someone dying in the next year doubles every eight years they live*) For tens of thousand of years, human life expectancy didn't change *) In recent centuries, the background mortality rate has significantly decreased, but the eight year "Gompertz curve" doubling of mortality remains unchanged*) Some animals do not have this mortality doubling characteristic; they are said to be "negligibly senescent", "biologically immortal", or "ageless"*) An example: Galapagos tortoises*) The concept of "hallmarks of aging" - and different lists of these hallmarks*) Theories of aging: wear-and-tear vs. programmed obsolescence*) Evolution and aging: two different strategies that species can adopt*) Wear-and-tear of teeth - as seen from a programmed aging point-of-view*) The case for a pragmatic approach*) Dietary restriction and healthier aging*) The potential of computational biology system models to generate better understanding of linkages between different hallmarks of aging*) Might some hallmarks, for example telomere shortening or epigenetic damage, prove more fundamental than others?*) Special challenges posed by damage in the proteins in the scaffolding between cells*) What's required to accelerate the advent of "longevity escape velocity"*) Excitement and questions over the funding available to Altos Labs*) Measuring timescales in research dollars rather than years*) Reasons for optimism for treatments of some of the hallmarks, for example with senolytics, but others aren't being properly addressed*) Breakthrough progress with the remaining hallmarks could be achieved with $5-10B investment each*) Adding some extra for potential unforeseen hallmarks, that sums to a total of around $100B before therapies for all aspects of aging could be in major clinical trials*) Why such an expenditure is in principle relatively easily affordable*) Reflections on moral and ethical objections to treatments against aging*) Overpopulation, environmental strains, resource sustainability, and net zero impact*) Aging as the single largest cause of death in the world - in all countries*) Andrew's current and forthcoming projects, including a book on options for funding science with the biggest impact*) Looking forward to "being more tortoise".Music: Spike Protein, by Koi Discovery, available under CC0 1.0 Public Domain Declaration

Avian or bird flu is normally seasonal, disappearing as migratory birds leave for winter. However a new strain which seems to spread more easily between wild birds and into poultry has led to the deaths of far more birds than usual. David Steel, Nature Reserve Manager on the Isle of May relates his observations of the effects on seabirds. And Nicola Lewis, Director of the Worldwide Influenza Centre at the Francis Crick Institute tells us why this particular stain is so severe. Climategate was a strange kind of scandal, based entirely on misinformation pushed by climate change deniers. In his new book Hot air, shortlisted for the Royal Society Insight Investment science book prize, Climate scientist Peter Stott assess the impact of their campaign. Pong was a very basic video game developed in the 1970s, now Australian researchers have trained human brain cells in a dish to play the game, Dr Brett Kagan from Cortical Labs explains why.

According to the World Health Organisation, air pollution causes 7 million premature deaths every year. We've known for a long time that air pollution causes lots of health problems, including lung cancer – but exactly how the two were linked was somewhat of mystery. Last week, a team from the Francis Crick Institute and University College London presented findings that shed new light on the role between air pollution and lung cancer. And, in doing so, could make us rethink how cancer develops. Madeleine Finlay speaks to the Guardian's science correspondent Hannah Devlin about how scientists uncovered this link – and what it might mean for the future of the field.. Help support our independent journalism at theguardian.com/sciencepod

Welcome back to another episode of the Plant Based News podcast! Today we are joined by certified medical doctor, plant-based healer and nutrition specialist Dr. Brooke Goldner, founder of VeganMedicalDoctor.com, GoodbyeLupus.com, and is known as the creator of the Hyper-nourishing Healing Protocol for Lupus Recovery. We are pleased to welcome Dr. Goldner on this episode of the PBN Podcast to talk more in depth about her own inspiring life story and journey of overcoming lupus. Follow Dr Brooke Goldner on Instagram here - https://www.instagram.com/goodbyelupus/ Find out more about Dr Brooke Goldner here - https://www.goodbyelupus.com/about-dr-g/ The PBN Podcast is hosted and produced by Robbie Lockie, Edited by Phil Marriott. 00:00:00 An introduction to Dr. Brooke Goldner 00:04:06 Exciting news about the Francis Crick Institute study of the rise of auto immune diseases 00:07:00 What are the tricks and tips to help people move away from their food addictions? 00:12:30 The effects of diet in conjunction with the onset of covid-19 00:19:00 How a “hyper-nourishment” diet can prevent and reverse chronic illness 00:41:00 What is the difference between a whole-food plant-based diet and a vegan diet? 00:54:48 Understanding the hesitancy surrounding vaccines 00:59:55 Is Dr. Brooke Goldner frustrated that the media don't appear to be discussing the benefits of a nourishing plant-based diet to combat the symptoms of covid? 01:06:05 What would a perfect day look like if someone wants to switch to a more nourishing diet?